ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

1. **NAME OF THE MEDICINAL PRODUCT**

   Briviact 10 mg film-coated tablets  
   Briviact 25 mg film-coated tablets  
   Briviact 50 mg film-coated tablets  
   Briviact 75 mg film-coated tablets  
   Briviact 100 mg film-coated tablets

2. **QUALITATIVE AND QUANTITATIVE COMPOSITION**

   **Briviact 10 mg film-coated tablets**
   Each film-coated tablet contains 10 mg brivaracetam.

   **Briviact 25 mg film-coated tablets**
   Each film-coated tablet contains 25 mg brivaracetam.

   **Briviact 50 mg film-coated tablets**
   Each film-coated tablet contains 50 mg brivaracetam.

   **Briviact 75 mg film-coated tablets**
   Each film-coated tablet contains 75 mg brivaracetam.

   **Briviact 100 mg film-coated tablets**
   Each film-coated tablet contains 100 mg brivaracetam.

   **Excipient(s) with known effect:**

   **Briviact 10 mg film-coated tablets**
   Each 10 mg film-coated tablet contains 88 mg lactose.

   **Briviact 25 mg film-coated tablets**
   Each 25 mg film-coated tablet contains 94 mg lactose.

   **Briviact 50 mg film-coated tablets**
   Each 50 mg film-coated tablet contains 189 mg lactose.

   **Briviact 75 mg film-coated tablets**
   Each 75 mg film-coated tablet contains 283 mg lactose.

   **Briviact 100 mg film-coated tablets**
   Each 100 mg film-coated tablet contains 377 mg lactose.

   For the full list of excipients, see section 6.1.

3. **PHARMACEUTICAL FORM**

   Film-coated tablet (tablets)

   **Briviact 10 mg film-coated tablets**
White to off-white, round film-coated tablets of 6.5 mm in diameter and debossed with ‘u10’ on one side.

**Briviact 25 mg film-coated tablets**
Grey, oval film-coated tablets with dimensions of 8.9 mm x 5.0 mm and debossed with ‘u25’ on one side.

**Briviact 50 mg film-coated tablets**
Yellow, oval film-coated tablets with dimensions of 11.7 mm x 6.6 mm and debossed with ‘u50’ on one side.

**Briviact 75 mg film-coated tablets**
Purple, oval film-coated tablets with dimensions of 13.0 mm x 7.3 mm debossed with ‘u75’ on one side.

**Briviact 100 mg film-coated tablets**
Green-grey, oval film-coated tablets with dimensions of 14.5 mm x 8.1 mm and debossed with ‘u100’ on one side.

4. **CLINICAL PARTICULARS**

4.1 **Therapeutic indications**

Briviact is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy.

4.2 **Posology and method of administration**

**Posology**

The recommended starting dose is either 50 mg/day or 100 mg/day based on physician assessment of required seizure reduction versus potential side effects. The dose should be administered in two equally divided doses, once in the morning and once in the evening. Based on individual patient response and tolerability, the dose may be adjusted in the dose range of 50 mg/day to 200 mg/day.

**Missed doses**

If patients missed one dose or more, it is recommended that they take a single dose as soon as they remember and take the following dose at the usual morning or evening time. This may avoid the brivaracetam plasma concentration falling below the efficacy level and prevent breakthrough seizures from occurring.

**Discontinuation**

If brivaracetam has to be discontinued it is recommended to withdraw it gradually by 50 mg/day on a weekly basis. After 1 week of treatment at 50 mg/day, a final week of treatment at the dose of 20 mg/day is recommended.

**Special populations**

*Elderly (65 years of age and above)*

No dose adjustment is needed in elderly patients (see section 5.2). The clinical experience in patients ≥ 65 years is limited.

*Renal impairment*

No dose adjustment is needed in patients with impaired renal function (see section 5.2). Brivaracetam is not recommended in end-stage renal disease patients undergoing dialysis due to lack of data.
Hepatic impairment
Exposure to brivaracetam was increased in patients with chronic liver disease. A 50 mg/day starting dose should be considered. A maximum daily dose of 150 mg administered in 2 divided doses is recommended for all stages of hepatic impairment (see section 4.4 and 5.2).

Paediatric population
The safety and efficacy of brivaracetam in children aged less than 16 years have not yet been established. Currently available data are described in section 4.8, 5.1, and 5.2 but no recommendation on a posology can be made.

Method of administration
Brivaracetam film-coated tablets must be taken orally swallowed in whole with liquid and may be taken with or without food (see section 5.2).

4.3 Contraindications
Hypersensitivity to the active substance or other pyrrolidone derivatives or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use
Suicidal ideation and behaviour
Suicidal ideation and behaviour have been reported in patients treated with anti-epileptic drugs (AEDs), including brivaracetam, in several indications. A meta-analysis of randomized placebo-controlled trials of AEDs has also shown a small increased risk of suicidal ideation and behaviour. The mechanism of this risk is not known and the available data do not exclude the possibility of an increased risk for brivaracetam.
Patients should be monitored for signs of suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should any signs of suicidal ideation or behaviour emerge.

Hepatic impairment
There are limited clinical data on the use of brivaracetam in patients with pre-existing hepatic impairment. Dose adjustments are recommended for patients with hepatic impairment (see section 4.2).

Lactose intolerance
Brivaracetam film-coated tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

4.5 Interaction with other medicinal products and other forms of interaction
Formal interaction studies have only been performed in adults.

Pharmacodynamic interactions
Concomitant treatment with levetiracetam
In the clinical studies, although the numbers were limited, there was no observed benefit of brivaracetam versus placebo in patients taking levetiracetam concurrently. No additional safety or tolerability concern was observed (see section 5.1).
Interaction with alcohol
In a pharmacokinetic and pharmacodynamic interaction study between brivaracetam 200 mg single dose and ethanol 0.6 g/L continuous infusion in healthy subjects, there was no pharmacokinetic interaction but brivaracetam approximately doubled the effect of alcohol on psychomotor function, attention and memory. Intake of brivaracetam with alcohol is not recommended.

Pharmacokinetic interactions

Effects of other agents on the pharmacokinetics of brivaracetam
In vitro data suggest that brivaracetam has a low interaction potential. The main disposition pathway of brivaracetam is by CYP-independent hydrolysis. A second disposition pathway involves hydroxylation mediated by CYP2C19 (see section 5.2).

Brivaracetam plasma concentrations may increase when coadministered with CYP2C19 strong inhibitors (e.g. fluconazole, fluvoxamine), but the risk of a clinically relevant CYP2C19-mediated interaction is considered to be low.

Rifampicin
In healthy subjects, coadministration with the strong enzyme inducer rifampicin (600 mg/day for 5 days), decreased brivaracetam area under the plasma concentration curve (AUC) by 45 %. Prescribers should consider adjusting the brivaracetam dose in patients starting or ending treatment with rifampicin.

Strong enzyme inducing AEDs
Brivaracetam plasma concentrations are decreased when coadministered with strong enzyme inducing AEDs (carbamazepine, phenobarbital, phenytoin) but no dose adjustment is required (see table 1).

Other enzyme inducers
Other strong enzyme inducers (such as St John’s wort (Hypericum perforatum)) may also decrease the systemic exposure of brivaracetam. Therefore, starting or ending treatment with St John’s wort should be done with caution.

Effects of brivaracetam on other medicinal products
Brivaracetam given 50 or 150 mg/day did not affect the AUC of midazolam (metabolised by CYP3A4). The risk of clinically relevant CYP3A4 interactions is considered to be low.

In vitro studies have shown that brivaracetam exhibits little or no inhibition of CYP450 isoforms except for CYP2C19. Brivaracetam may increase plasma concentrations of medicinal products metabolised by CYP2C19 (e.g. lanzoprazole, omeprazole, diazepam). When tested in vitro brivaracetam did not induce CYP1A1/2 but induced CYP3A4 and CYP2B6. No CYP3A4 induction was found in vivo (see midazolam above). CYP2B6 induction has not been investigated in vivo and brivaracetam may decrease plasma concentrations of medicinal products metabolised by CYP2B6 (e.g. efavirenz). In vitro interaction studies to determine the potential inhibitory effects on transporters concluded that there were no clinically relevant effects, except for OAT3. In vitro, Brivaracetam inhibits OAT3 with a half maximal inhibitory concentration 42-fold higher than the C_max at the highest clinical dose. Brivaracetam 200mg/day may increase plasma concentrations of medicinal products transported by OAT3.

Antiepileptic drugs
Potential interactions between brivaracetam (50 mg/day to 200 mg/day) and other AEDs were investigated in a pooled analysis of plasma drug concentrations from all phase 2-3 studies, in a population pharmacokinetic analysis of placebo-controlled phase 2-3 studies, and in dedicated drug-drug interaction studies (for the following AEDs: carbamazepine, lamotrigine, phenytoin and topiramate). The effect of the interactions on the plasma concentration is summarised in table 1 (increase is indicated as “↑” and decrease as “↓”, area under the plasma concentration versus time curve as “AUC”, maximum observed concentration as C_max).
Table 1: Pharmacokinetic interactions between brivaracetam and other AEDs

<table>
<thead>
<tr>
<th>AED coadministered</th>
<th>Influence of AED on brivaracetam plasma concentration</th>
<th>Influence of brivaracetam on AED plasma concentration</th>
</tr>
</thead>
</table>
| Carbamazepine        | AUC 29 % ↓  
|                      | C_{max} 13 % ↓  
|                      | No dose adjustment required                         | Carbamazepine - None  
|                      |                                                     | Carbamazepine-epoxide ↑  
|                      |                                                     | (See below)  
|                      |                                                     | No dose adjustment required. |
| Clobazam             | No data available                                    | None                                                |
| Clonazepam           | No data available                                    | None                                                |
| Lacosamide           | No data available                                    | None                                                |
| Lamotrigine          | None                                                 | None                                                |
| Levetiracetam        | None                                                 | None                                                |
| Oxcarbazepine        | None                                                 | None (monohydroxy derivative, MHD)                  |
| Phenobarbital        | AUC 19 % ↓  
|                      | No dose adjustment required                         | None                                                |
| Phenytoin            | AUC 21 % ↓  
|                      | No dose adjustment required                         | None                                                |
|                      |  
|                      |  
|                      |  
| Pregabalin           | No data available                                    | None                                                |
| Topiramate           | None                                                 | None                                                |
| Valproic acid        | None                                                 | None                                                |
| Zonisamide           | No data available                                    | None                                                |

*based on a study involving the administration of a supratherapeutic dose of 400 mg/day brivaracetam.

**Carbamazepine**

Brivaracetam is a moderate reversible inhibitor of epoxide hydrolase resulting in an increased concentration of carbamazepine epoxide, an active metabolite of carbamazepine. In controlled studies, the carbamazepine epoxide plasma concentration increased by a mean of 37 %, 62 % and 98 % with little variability at brivaracetam doses of 50 mg/day, 100 mg/day and 200 mg/day respectively. No safety risks were observed. There was no additive effect of brivaracetam and valproate on the AUC of carbamazepine epoxide.

**Oral contraceptives**

Co-administration of brivaracetam (100 mg/day) with an oral contraceptive containing ethinylestradiol (0.03 mg) and levonorgestrel (0.15 mg) did not influence the pharmacokinetics of either substance. When brivaracetam was coadministered at a dose of 400 mg/day (twice the recommended maximum daily dose) with an oral contraceptive containing ethinylestradiol (0.03 mg) and levonorgestrel (0.15 mg), a reduction in estrogen and progestin AUCs of 27 % and 23 %, respectively, was observed without impact on suppression of ovulation. There was generally no change in the concentration-time profiles of the endogenous markers estradiol, progesterone, luteinizing hormone (LH), follicle stimulating hormone (FSH), and sex hormone binding globulin (SHBG).

4.6 Fertility, pregnancy and lactation

Women of childbearing potential

Physicians should discuss family planning and contraception with women of childbearing potential taking brivaracetam (see Pregnancy).

If a woman decides to become pregnant, the use of brivaracetam should be carefully re-evaluated.

**Pregnancy**

*Risk related to epilepsy and antiepileptic medicinal products in general*
For all anti-epileptic drugs, it has been shown that in the offspring of treated women with epilepsy, the prevalence of malformations is two to three times greater than the rate of approximately 3% in the general population. In the treated population, an increase in malformations has been noted with polytherapy; however, the extent to which the treatment and/or the underlying condition is responsible has not been elucidated. Discontinuation of anti-epileptic treatments may result in exacerbation of the disease which could be harmful to the mother and the foetus.

Risk related to brivaracetam

There is a limited amount of data from the use of brivaracetam in pregnant women. There is no data on placental transfer in humans, but brivaracetam was shown to readily cross the placenta in rats (see section 5.3). The potential risk for humans is unknown. Animal studies did not detect any teratogenic potential of brivaracetam (see section 5.3).

In clinical studies, brivaracetam was used as adjunctive therapy and when it was used with carbamazepine, it induced a dose-related increase in the concentration of the active metabolite, carbamazepine-epoxide (see section 4.5). There is insufficient data to determine the clinical significance of this effect in pregnancy.

As a precautionary measure, brivaracetam should not be used during pregnancy unless clinically necessary i.e. (if the benefit to the mother clearly outweighs the potential risk to the foetus).

Breast-feeding

It is unknown whether brivaracetam is excreted in human breast milk. Studies in rats have shown excretion of brivaracetam in breast milk (see section 5.3). A decision should be made whether to discontinue breastfeeding or to discontinue brivaracetam, taking into account the benefit of the medicinal product to the mother. In case of co-administration of brivaracetam and carbamazepine, the amount of carbamazepine-epoxide excreted in breast milk could increase. There is insufficient data to determine the clinical significance.

Fertility

No human data on the effect of brivaracetam on fertility are available. In rats, there was no effect on fertility with brivaracetam (see section 5.3).

4.7 Effects on ability to drive and use machines

Brivaracetam has minor or moderate influence on the ability to drive and use machines.

Due to possible differences in individual sensitivity some patients might experience somnolence, dizziness, and other central nervous system (CNS) related symptoms. Patients should be advised not to drive a car or to operate other potentially hazardous machines until they are familiar with the effects of brivaracetam on their ability to perform such activities.

4.8 Undesirable effects

Summary of the safety profile

In all controlled and uncontrolled trials in patients with epilepsy, 2,388 subjects have received brivaracetam, of whom 1,740 have been treated for ≥ 6 months, 1,363 for ≥ 12 months, 923 for ≥ 24 months and 569 for ≥ 60 months (5 years).

The most frequently reported adverse reactions (≥ 10%) with brivaracetam treatment were: somnolence (14.3%) and dizziness (11.0%). They were usually mild to moderate in intensity. Somnolence and fatigue (8.2%) were reported at a higher incidence with increasing dose. The types of adverse reactions reported during the first 7 days of treatment were similar to those reported for the overall treatment period.
The discontinuation rate due to adverse reactions was 3.5 %, 3.4 % and 4.0 % for patients randomized to brivaracetam at respectively the dose of 50 mg/day, 100 mg/day and 200 mg/day and 1.7 % for patients randomized to placebo. The adverse reactions most frequently resulting in discontinuation of brivaracetam therapy were dizziness (0.8 %) and convulsion (0.8 %).

Tabulated list of adverse reactions

In the table below, adverse reactions, which were identified based on review of the full brivaracetam clinical studies safety database, are listed by System Organ Class and frequency. The frequencies are defined as follows: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

<table>
<thead>
<tr>
<th>System organ class</th>
<th>Frequency</th>
<th>Adverse reactions from clinical trials</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infections and infestations</td>
<td>Common</td>
<td>Influenza</td>
</tr>
<tr>
<td>Blood and lymphatic system disorders</td>
<td>Uncommon</td>
<td>Neutropenia</td>
</tr>
<tr>
<td>Metabolism and nutrition disorders</td>
<td>Common</td>
<td>Decreased appetite</td>
</tr>
<tr>
<td>Immune system disorders</td>
<td>Uncommon</td>
<td>Type I hypersensitivity</td>
</tr>
<tr>
<td>Psychiatric disorders</td>
<td>Common</td>
<td>Depression, anxiety, insomnia, irritability</td>
</tr>
<tr>
<td></td>
<td>Uncommon</td>
<td>Suicidal ideation, psychotic disorder, aggression, agitation</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>Very common</td>
<td>Dizziness, somnolence</td>
</tr>
<tr>
<td></td>
<td>Common</td>
<td>Convulsion, vertigo</td>
</tr>
<tr>
<td>Respiratory, thoracic and mediastinal disorders</td>
<td>Common</td>
<td>Upper respiratory tract infections, cough</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>Common</td>
<td>Nausea, vomiting, constipation</td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td>Common</td>
<td>Fatigue</td>
</tr>
</tbody>
</table>

Description of selected adverse reactions

Neutropenia has been reported in 0.5 % (6/1099) brivaracetam patients and 0 % (0/459) placebo patients. Four of these subjects had decreased neutrophil counts at baseline, and experienced additional decrease in neutrophil counts after initiation of brivaracetam treatment. None of the 6 cases of neutropenia were severe, required any specific treatment or led to discontinuation of brivaracetam and none had associated infections.

Suicidal ideation has been reported in 0.3 % (3/1099) brivaracetam patients and 0.7 % (3/459) placebo patients. In the short-term clinical studies of brivaracetam in epilepsy patients, there were no cases of completed suicide and suicide attempt, however both have been reported in open-label extension studies (see section 4.4).

Reactions suggestive of immediate (Type I) hypersensitivity have been reported in a small number of brivaracetam patients (9/3022) during clinical development.

Open-label extension studies

In patients who were followed up in the open-label extension studies for up to 8 years, the safety profile was similar to that observed in the short-term, placebo-controlled studies.
Paediatric population

There are limited safety data from open-label studies in children from 1 month to < 16 years of age. A total of 152 children (1 month to < 16 years of age) were treated with brivaracetam in a pharmacokinetic study and the related follow up study. From the limited available data, the most frequently reported TEAEs considered drug-related by the investigator were somnolence (10 %), decreased appetite (8 %), fatigue (5 %) and weight decreased (5 %). The safety profile appears to be consistent with that known in adults. No data are available on neurodevelopment. Currently, no clinical data are available in neonates.

Elderly

Of the 130 elderly subjects enrolled in the brivaracetam phase 2/3 development program (44 with epilepsy), 100 were 65-74 years of age and 30 were 75-84 years of age. The safety profile in elderly patients appears to be similar to that observed in younger adult patients.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

4.9 Overdose

Symptoms

There is limited clinical experience with brivaracetam overdose in humans. Somnolence and dizziness have been reported in a healthy subject taking a single dose of 1,400 mg of brivaracetam.

Management of overdose

There is no specific antidote for overdose with brivaracetam. Treatment of an overdose should include general supportive measures. Since less than 10 % of brivaracetam is excreted in urine, haemodialysis is not expected to significantly enhance brivaracetam clearance (see section 5.2).

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: antiepileptics, other antiepileptics, ATC code: N03AX23

Mechanism of action

Brivaracetam displays a high and selective affinity for synaptic vesicle protein 2A (SV2A), a transmembrane glycoprotein found at presynaptic level in neurons and in endocrine cells. Although the exact role of this protein remains to be elucidated it has been shown to modulate exocytosis of neurotransmitters. Binding to SV2A is believed to be the primary mechanism for brivaracetam anticonvulsant activity.

Clinical efficacy and safety

The efficacy of brivaracetam for the adjunctive therapy of partial-onset seizures (POS) was established in 3 randomized, double-blind, placebo-controlled, fixed-dose, multi-center studies in subjects 16 years of age and older. The daily dose of brivaracetam ranged from 5 to 200 mg/day across these studies. All studies had an 8-week baseline period followed by a 12-week treatment period with no up-
titration. 1,558 patients received study drug of which 1,099 received brivaracetam. Study enrollment criteria required that patients have uncontrolled POS despite treatment with either 1 or 2 concomitant AEDs. Patients were required to have at least 8 POS during the baseline period. The primary endpoints in the phase 3 studies were the percent reduction in POS frequency over placebo and the 50 % responder rate based on 50 % reduction in POS frequency from baseline. The most commonly taken AEDs at the time of study entry were carbamazepine (40.6 %), lamotrigine (25.2 %), valproate (20.5 %), oxcarbazepine (16.0 %), topiramate (13.5 %), phenytoin (10.2 %) and levetiracetam (9.8 %). The median baseline seizure frequency across the 3 studies was 9 seizures per 28 days. Patients had a mean duration of epilepsy of approximately 23 years. The efficacy outcomes are summarized in Table 2. Overall, brivaracetam was efficacious for the adjunctive treatment of partial onset seizures in patients 16 years of age and older between 50 mg/day and 200 mg/day.

Table 2: Key Efficacy Outcomes for Partial Onset Seizure Frequency per 28 Days

<table>
<thead>
<tr>
<th>Study</th>
<th>Placebo</th>
<th>Brivaracetam *</th>
<th>Statistically significant (p-value)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>50 mg/day</td>
<td>100 mg/day</td>
</tr>
<tr>
<td>Study N01253(1)</td>
<td></td>
<td>n= 96</td>
<td>n= 101</td>
</tr>
<tr>
<td>50 % Responder rate</td>
<td>16.7</td>
<td>32.7 *</td>
<td>~</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(p=0.008)</td>
<td></td>
</tr>
<tr>
<td>Percent reduction over placebo (%)</td>
<td>NA</td>
<td>22.0 *</td>
<td>~</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(p=0.0040)</td>
<td></td>
</tr>
<tr>
<td>Study N01252(1)</td>
<td></td>
<td>n= 100</td>
<td>n= 99</td>
</tr>
<tr>
<td>50 % Responder rate</td>
<td>20.0</td>
<td>27.3</td>
<td>36.0 *</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(p=0.372)</td>
<td>(p=0.023)</td>
</tr>
<tr>
<td>Percent reduction over placebo (%)</td>
<td>NA</td>
<td>9.2</td>
<td>20.5 *</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(p=0.0274)</td>
<td>(p=0.0097)</td>
</tr>
<tr>
<td>Study N01358</td>
<td></td>
<td>n= 259</td>
<td>n= 252</td>
</tr>
<tr>
<td>50% Responder rate</td>
<td>21.6</td>
<td>~</td>
<td>38.9</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(p=0.001)</td>
</tr>
<tr>
<td>Percent reduction over placebo (%)</td>
<td>NA</td>
<td>~</td>
<td>22.8 *</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(p=0.001)</td>
</tr>
</tbody>
</table>

n = randomised patients who received at least 1 dose of study medication

~ Dose not studied

* Statistically significant

(1) Approximately 20 % of the patients were on concomitant levetiracetam
(2) The primary outcome for N01252 did not achieve statistical significance based on the sequential testing procedure. The 100 mg/day dose was nominally significant.

In clinical studies, a reduction in seizure frequency over placebo was higher with the dose of 100 mg/day than with 50 mg/day. Apart from dose-dependent increases in incidences of somnolence and fatigue brivaracetam 50 mg/day and 100 mg/day had a similar safety profile including CNS-related AEs and with long-term use.

Figure 1 shows the percentage of patients (excluding patients with concomitant levetiracetam) by category of reduction from baseline in POS frequency per 28 days in all 3 studies. Patients with more than a 25 % increase in POS are shown at left as “worse”. Patients with an improvement in percent reduction in baseline POS frequency are shown in the 4 right-most categories. The percentages of patients with at least a 50 % reduction in seizure frequency were 20.3 %, 34.2 %, 39.5 %, and 37.8 % for placebo, 50 mg/day, 100 mg/day, and 200 mg/day, respectively.
In a pooled analysis of the three pivotal trials, no differences in efficacy (measured as 50% responder rate) was observed within the dose range of 50 mg/day to 200 mg/day when brivaracetam is combined with inducing or non-inducing AEDs. In clinical studies 2.5% (4/161), 5.1% (17/332) and 4.0% (10/249) of the patients on brivaracetam 50 mg/day, 100 mg/day and 200 mg/day respectively became seizure free during the 12-week treatment period compared with 0.5% (2/418) on placebo.

Improvement in the median percent reduction in seizure frequency per 28 days has been observed in patients with type IC seizure (secondary generalized tonic-clonic seizures) at baseline treated with brivaracetam (66.6% (n=62), 61.2% (n=100) and 82.1% (n=75) of the patients on brivaracetam 50 mg/day, 100 mg/day and 200 mg/day respectively as compared to placebo 33.3% (n=115)).

The efficacy of brivaracetam in monotherapy has not been established. Brivaracetam is not recommended for use in monotherapy.

**Treatment with levetiracetam**

In two phase 3 randomised placebo-controlled studies, levetiracetam was administered as concomitant AED in about 20% of the patients. Although the number of subjects is limited, there was no observed benefit of brivaracetam versus placebo in patients taking levetiracetam concurrently which may reflect competition at the SV2A binding site. No additional safety or tolerability concerns were observed.

In a third study, a pre-specified analysis demonstrated efficacy over placebo for 100 mg/day and 200 mg/day in patients with prior exposure to levetiracetam. The lower efficacy observed in these patients compared to the levetiracetam-naïve patients was likely due to the higher number of prior AEDs used and higher baseline seizure frequency.

**Elderly (65 years of age and above)**

The three pivotal double-blind placebo-controlled studies included 38 elderly patients aged between 65 and 80 years. Although data are limited, the efficacy was comparable to younger subjects.

**Open label extension studies**

Across all studies, 81.7% of the patients who completed randomized studies were enrolled in the long-term open-label extension studies. From entry into the randomized studies, 5.3% of the subjects exposed to brivaracetam for 6 months (n=1,500) were seizure free compared to 4.6% and 3.7% for
subjects exposed for 12 months (n=1,188) and 24 months (n=847), respectively. However, as a high proportion of subjects (26%) discontinued from the open-label studies due to lack of efficacy, a selection bias may have occurred, as the subjects who stayed in the study responded better than those who have terminated prematurely.

Paediatric population

The efficacy and tolerability of brivaracetam in paediatric patients have not been established (see section 4.2). Brivaracetam was evaluated in these patients in short term open label pharmacokinetic study and an ongoing open-label extension study, in 152 subjects from 1 month to 16 years of age (see section 5.2).

The European Medicines Agency has deferred the obligation to submit the results of studies with brivaracetam in one or more subsets of the paediatric population in epilepsy with partial onset seizures.

5.2 Pharmacokinetic properties

Brivaracetam film-coated tablets, oral solution and solution for intravenous injection show the same AUC, while the maximum plasma concentration is slightly higher after intravenous administration. Brivaracetam exhibits linear and time-independent pharmacokinetics with low intra- and inter-subject variability, and features complete absorption, very low protein binding, renal excretion following extensive biotransformation, and pharmacologically inactive metabolites.

Absorption

Brivaracetam is rapidly and completely absorbed after oral administration and the absolute bioavailability is approximately 100 %. The median $t_{\text{max}}$ for tablets taken without food is 1 hour ($t_{\text{max}}$ range is 0.25 to 3 h).

Coadministration with a high-fat meal slowed down the absorption rate (median $t_{\text{max}}$ 3 h) and decreased the maximum plasma concentration (37 % lower) of brivaracetam, while the extent of absorption remained unchanged.

Distribution

Brivaracetam is weakly bound ($\leq 20 \%$) to plasma proteins. The volume of distribution is 0.5 L/kg, a value close to that of the total body water.

Due to its lipophylicity (Log P) brivaracetam has high cell membrane permeability.

Biotransformation

Brivaracetam is primarily metabolized by hydrolysis of the amide moiety to form the corresponding carboxylic acid (approximately 60 % the elimination), and secondarily by hydroxylation on the propyl side chain (approximately 30 % the elimination). The hydrolysis of the amide moiety leading to the carboxylic acid metabolite (34 % of the dose in urine) is supported by hepatic and extra-hepatic amidase. In vitro, the hydroxylation of brivaracetam is mediated primarily by CYP2C19. Both metabolites, are further metabolised forming a common hydroxylated acid formed predominantly by hydroxylation of the propyl side chain on the carboxylic acid metabolite (mainly by CYP2C9). In vivo, in human subjects possessing ineffective mutations of CYP2C19, production of the hydroxy metabolite is decreased 10-fold while brivaracetam itself is increased by 22 % or 42 % in individuals with one or both mutated alleles. The three metabolites are not pharmacologically active.

Elimination

Brivaracetam is eliminated primarily by metabolism and by excretion in the urine. More than 95 % of the dose, including metabolites, is excreted in the urine within 72 hours after intake. Less than 1 % of the dose is excreted in faeces and less than 10 % of brivaracetam is excreted unchanged in urine. The
terminal plasma half-life (t1/2) is approximately 9 hours. The total plasma clearance in patients was estimated to 3.6 L/h.

**Linearity**

Pharmacokinetics is dose-proportional from 10 to at least 600 mg.

**Interactions with medicinal products**

Brivaracetam is cleared by multiple pathways including renal excretion, non-CYP-mediated hydrolysis and CYP-mediated oxidations. *In vitro*, brivaracetam is not a substrate of human P-glycoprotein (P-gp), multidrug resistance proteins (MRP) 1 and 2, and likely not organic anion transporter polypeptide 1B1 (OATP1B1) and OATP1B3. *In vitro* assays showed that brivaracetam disposition should not be significantly affected by CYP (eg. CYP1A, 2C8, 2C9, 2D6 and 3A4) inhibitors.

In vitro, brivaracetam was not an inhibitor of the CYP1A2, 2A6, 2B6, 2C8, 2C9, 2D6, 3A4, or the transporters P-gp, BCRP, BSEP MRP2, MATE-K, MATE-1, OATP1B1, OATP1B3, OAT1 and OCT1 at clinically relevant concentrations. In vitro, brivaracetam did not induce CYP1A2.

**Pharmacokinetics in special patient groups**

**Elderly (65 years of age and above)**

In a study in elderly subjects (65 to 79 years old; with creatinine clearance 53 to 98 ml/min/1.73 m²) receiving brivaracetam 400 mg/day in bid administration, the plasma half-life of brivaracetam was 7.9 hours and 9.3 hours in the 65 to 75 and >75 years groups, respectively. The steady-state plasma clearance of brivaracetam was similar (0.76 ml/min/kg) to young healthy male subjects (0.83 ml/min/kg) (see section 4.2).

**Renal impairment**

A study in subjects with severe renal impairment (creatinine clearance <30 ml/min/1.73 m² and not requiring dialysis) revealed that the plasma AUC of brivaracetam was moderately increased (+21 %) relative to healthy controls, while the AUC of the acid, hydroxy and hydroxyacid metabolites were increased 3-, 4-, and 21-fold, respectively. The renal clearance of these non active metabolites was decreased 10-fold. The hydroxyacid metabolite did not reveal any safety concerns in non clinical studies. Brivaracetam has not been studied in patients undergoing hemodialysis (see section 4.2).

**Hepatic impairment**

A pharmacokinetic study in subjects with hepatic cirrhosis (Child-Pugh grades A, B, and C) showed similar increases in exposure to brivaracetam irrespective of disease severity (50 %, 57 % and 59 %), relative to matched healthy controls. (see section 4.2)

**Paediatric population**

In a pharmacokinetic study in 99 subjects aged 1 month to <16 years receiving brivaracetam oral solution, plasma concentrations were shown to be dose-proportional in all age groups. Population pharmacokinetics modeling indicated that the dose of 2.0 mg/kg twice a day provides the same steady-state average plasma concentration as in adults receiving 100 mg twice daily.

**Body weight**

A 40 % decrease in steady-state plasma concentration has been estimated across a body weight range from 46 kg to 115 kg. However, this is not considered to be a clinically relevant difference.

**Gender**

There are no clinically relevant differences in the pharmacokinetics of brivaracetam by gender.

**Race**
The pharmacokinetics of brivaracetam was not significantly affected by race (Caucasian, Asian) in a population pharmacokinetic modeling from epilepsy patients. The number of patients with other ethnic background was limited.

**Pharmacokinetic/pharmacodynamics relationship**

The EC50 (brivaracetam plasma concentration corresponding to 50 % of the maximum effect) was estimated to be 0.57 mg/L. This plasma concentration is slightly above the median exposure obtained after brivaracetam doses of 50 mg/day. Further seizure frequency reduction is obtained by increasing the dose to 100 mg/day and reaches a plateau at 200 mg/day.

5.3 **Preclinical safety data**

In safety pharmacology studies, the predominant effects were CNS related (mainly transient CNS depression and decreased spontaneous locomotor activity) seen at multiples (greater than 50 fold) of the pharmacologically active dose of brivaracetam, 2 mg/kg. Learning and memory function were not affected.

Findings not observed in clinical studies, but seen in the repeated-dose toxicology dog studies at exposure similar to the clinical plasma AUC, were hepatotoxic effects (mainly porphyria). However, toxicological data accumulated on brivaracetam and on a structurally-related compound indicate that the dog liver changes have developed through mechanisms not relevant for humans. No adverse liver changes were seen in rats and monkeys following chronic administration of brivaracetam at 5- and 42-fold the clinical AUC exposure. In monkeys, CNS signs (prostrate, loss of balance, clumsy movements) occurred at 64 fold the clinical Cmax, these effects being less apparent over time.

Genotoxicity studies have not detected any mutagenic or clastogenic activity. Carcinogenicity studies did not indicate any oncogenic potential in rats, whereas increased incidences of hepatocellular tumors in male mice are considered to result of a non-genotoxic, mode of action linked to a phenobarbitone-like liver enzyme induction, which is a known rodent specific phenomenon.

Brivaracetam did not affect male or female fertility and has demonstrated no teratogenic potential in either rat or rabbit. Embryotoxicity was observed in rabbits at a maternal toxic dose of brivaracetam with an exposure level 8-fold the clinical AUC exposure at the maximum recommended dose. In rats, brivaracetam was shown to readily cross the placenta and to be excreted in milk of lactating rats with concentrations similar to maternal plasma levels.

Brivaracetam did not show any dependence potential in rats.

**Juvenile animals studies**

In juvenile rats, brivaracetam exposure levels 6- to 15-fold the clinical AUC exposure at the maximum recommended dose induced developmental adverse effects (i.e. mortality, clinical signs, decreased body weight and lower brain weight). There were no adverse effects on CNS function, neuropathological and brain histopathological examination. In juvenile dogs, the brivaracetam-induced changes at the exposure level 6- fold the clinical AUC were similar to those observed in adult animals. There were no adverse effects in any of the standard developmental or maturation endpoints.

6. **PHARMACEUTICAL PARTICULARS**

6.1 **List of excipients**

**Core**

Croscarmellose Sodium, Lactose monohydrate
Coating

**Briviact 10 mg film-coated tablets**
Polyvinyl alcohol
Titanium dioxide (E171)
Macrogol 3350
Talc.

**Briviact 25 mg film-coated tablets**
Polyvinyl alcohol
Titanium dioxide (E171)
Macrogol 3350
Talc
Iron oxide yellow (E172)
Iron oxide black (E172).

**Briviact 50 mg film-coated tablets**
Polyvinyl alcohol
Titanium dioxide (E171)
Macrogol 3350
Talc
Iron oxide yellow (E172)
Iron oxide red (E172).

**Briviact 75 mg film-coated tablets**
Polyvinyl alcohol
Titanium dioxide (E171)
Macrogol 3350
Talc
Iron oxide yellow (E172)
Iron oxide red (E172)
Iron oxide black (E172).

**Briviact 100 mg film-coated tablets**
Polyvinyl alcohol
Titanium dioxide (E171)
Macrogol 3350
Talc
Iron oxide yellow (E172)
Iron oxide black (E172)

### 6.2 Incompatibilities

Not applicable

### 6.3 Shelf life

4 years.

### 6.4 Special precautions for storage

This medicinal product does not require any special storage conditions.
6.5 Nature and contents of container

**Briviact 10 mg film-coated tablets**
- Packs of 14, 56 film-coated tablets and in multipacks containing 168 (3 packs of 56) film-coated tablets in PVC/PCTFE - Aluminium blisters
- Packs of 14 x 1 and 100 x 1 film-coated tablet in PVC/PCTFE - Aluminium blisters

**Briviact 25 mg film-coated tablets**
- Packs of 14, 56 film-coated tablets and in multipacks containing 168 (3 packs of 56) film-coated tablets in PVC/PCTFE - Aluminium blisters
- Packs of 14 x 1 and 100 x 1 film-coated tablet in PVC/PCTFE - Aluminium blisters

**Briviact 50 mg film-coated tablets**
- Packs of 14, 56 film-coated tablets and in multipacks containing 168 (3 packs of 56) film-coated tablets in PVC/PCTFE - Aluminium blisters
- Packs of 14 x 1 and 100 x 1 film-coated tablet in PVC/PCTFE - Aluminium blisters

**Briviact 75 mg film-coated tablets**
- Packs of 14, 56 film-coated tablets and in multipacks containing 168 (3 packs of 56) film-coated tablets in PVC/PCTFE - Aluminium blisters
- Packs of 14 x 1 and 100 x 1 film-coated tablet in PVC/PCTFE - Aluminium blisters

**Briviact 100 mg film-coated tablets**
- Packs of 14, 56 film-coated tablets and in multipacks containing 168 (3 packs of 56) film-coated tablets in PVC/PCTFE - Aluminium blisters
- Packs of 14 x 1 and 100 x 1 film-coated tablet in PVC/PCTFE - Aluminium blisters

Not all pack sizes may be marketed.

6.6 Special precautions for disposal

No special requirements.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

UCB Pharma S.A.
Allée de la Recherche 60
B-1070 Bruxelles
Belgium

8. MARKETING AUTHORISATION NUMBER(S)

EU/1/15/1073/001
EU/1/15/1073/002
EU/1/15/1073/003
EU/1/15/1073/004
EU/1/15/1073/005
EU/1/15/1073/006
EU/1/15/1073/007
EU/1/15/1073/008
EU/1/15/1073/009
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 14 January 2016

10. DATE OF REVISION OF THE TEXT

Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

1. NAME OF THE MEDICINAL PRODUCT

Briviact 10 mg/ml oral solution

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml contains 10 mg brivaracetam.

**Excipient(s) with known effect:**
Each ml of oral solution contains 239.8 mg sorbitol (E420), 1mg methyl parahydroxybenzoate (E218) and 1.16 mg sodium.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Oral solution
Slightly viscous, clear colourless to yellowish liquid.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Briviact is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy.

4.2 Posology and method of administration

**Posology**

The recommended starting dose is either 50 mg/day or 100 mg/day based on physician assessment of required seizure reduction versus potential side effects. The dose should be administered in two equally divided doses, once in the morning and once in the evening. Based on individual patient response and tolerability, the dose may be adjusted in the dose range of 50 mg/day to 200 mg/day.

**Missed doses**

If patients missed one dose or more, it is recommended that they take a single dose as soon as they remember and take the following dose at the usual morning or evening time. This may avoid the brivaracetam plasma concentration falling below the efficacy level and prevent breakthrough seizures from occurring.

**Discontinuation**

If brivaracetam has to be discontinued it is recommended to withdraw it gradually by 50 mg/day on a weekly basis. After 1 week of treatment at 50 mg/day, a final week of treatment at the dose of 20 mg/day is recommended.

**Special populations**

_Elderly (65 years of age and above)_
No dose adjustment is needed in elderly patients (see section 5.2). The clinical experience in patients ≥ 65 years is limited.

Renal impairment
No dose adjustment is needed in patients with impaired renal function (see section 5.2). Brivaracetam is not recommended in end-stage renal disease patients undergoing dialysis due to lack of data.

Hepatic impairment
Exposure to brivaracetam was increased in patients with chronic liver disease. A 50 mg/day starting dose should be considered. A maximum daily dose of 150 mg administered in 2 divided doses is recommended for all stages of hepatic impairment (see sections 4.4 and 5.2).

Paediatric population
The safety and efficacy of brivaracetam in children aged less than 16 years have not yet been established. Currently available data are described in section 4.8, 5.1, and 5.2 but no recommendation on a posology can be made.

Method of administration
Brivaracetam oral solution can be diluted in water or juice shortly before swallowing and may be taken with or without food (see section 5.2). A nasogastric tube or a gastrostomy tube may be used when administering brivaracetam oral solution.

4.3 Contraindications
Hypersensitivity to the active substance or other pyrrolidone derivatives or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

Suicidal ideation and behaviour
Suicidal ideation and behaviour have been reported in patients treated with anti-epileptic drugs (AEDs), including brivaracetam, in several indications. A meta-analysis of randomized placebo-controlled trials of AEDs has also shown a small increased risk of suicidal ideation and behaviour. The mechanism of this risk is not known and the available data do not exclude the possibility of an increased risk for brivaracetam. Patients should be monitored for signs of suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should any signs of suicidal ideation or behaviour emerge.

Hepatic impairment
There are limited clinical data on the use of brivaracetam in patients with pre-existing hepatic impairment. Dose adjustments are recommended for patients with hepatic impairment (see section 4.2).

Excipients

Sodium content
Brivaracetam oral solution contains sodium. To be taken into consideration by patients on a controlled sodium diet.

Fructose intolerance
The oral solution contains sorbitol (E420). Patients with rare hereditary problems of fructose intolerance should not take this medicine.
Excipients which may cause intolerance
The oral solution contains methyl parahydroxybenzoate (E218), which may cause allergic reactions (possibly delayed).

4.5 Interaction with other medicinal products and other forms of interaction

Formal interaction studies have only been performed in adults.

Pharmacodynamic interactions

Concomitant treatment with levetiracetam
In the clinical studies, although the numbers were limited, there was no observed benefit of brivaracetam versus placebo in patients taking levetiracetam concurrently. No additional safety or tolerability concern was observed (see section 5.1).

Interaction with alcohol
In a pharmacokinetic and pharmacodynamic interaction study between brivaracetam 200 mg single dose and ethanol 0.6 g/L continuous infusion in healthy subjects, there was no pharmacokinetic interaction but brivaracetam approximately doubled the effect of alcohol on psychomotor function, attention and memory. Intake of brivaracetam with alcohol is not recommended.

Pharmacokinetic interactions

Effects of other agents on the pharmacokinetics of brivaracetam
In vitro data suggest that brivaracetam has a low interaction potential. The main disposition pathway of brivaracetam is by CYP-independent hydrolysis. A second disposition pathway involves hydroxylation mediated by CYP2C19 (see section 5.2).

Brivaracetam plasma concentrations may increase when coadministered with CYP2C19 strong inhibitors (e.g. fluconazole, fluvoxamine), but the risk of a clinically relevant CYP2C19-mediated interaction is considered to be low.

Rifampicin
In healthy subjects, coadministration with the strong enzyme inducer rifampicin (600 mg/day for 5 days), decreased brivaracetam area under the plasma concentration curve (AUC) by 45%. Prescribers should consider adjusting the brivaracetam dose in patients starting or ending treatment with rifampicin.

Strong enzyme inducing AEDs
Brivaracetam plasma concentrations are decreased when coadministered with strong enzyme inducing AEDs (carbamazepine, phenobarbital, phenytoin) but no dose adjustment is required (see table 1).

Other enzyme inducers
Other strong enzyme inducers (such as St John’s wort (Hypericum perforatum)) may also decrease the systemic exposure of brivaracetam. Therefore, starting or ending treatment with St John’s wort should be done with caution.

Effects of brivaracetam on other medicinal products
Brivaracetam given 50 or 150 mg/day did not affect the AUC of midazolam (metabolised by CYP3A4). The risk of clinically relevant CYP3A4 interactions is considered to be low.

In vitro studies have shown that brivaracetam exhibits little or no inhibition of CYP450 isoforms except for CYP2C19. Brivaracetam may increase plasma concentrations of medicinal products metabolised by CYP2C19 (e.g. lanzoprazole, omeprazole, diazepam). When tested in vitro, brivaracetam did not induce CYP1A1/2 but induced CYP3A4 and CYP2B6. No CYP3A4 induction was found in vivo (see midazolam above). CYP2B6 induction has not been investigated in vivo and
brivaracetam may decrease plasma concentrations of medicinal products metabolised by CYP2B6 (e.g. efavirenz). In vitro, interaction studies to determine the potential inhibitory effects on transporters concluded that there were no clinically relevant effects, except for OAT3. In vitro, brivaracetam inhibits OAT3 with a half maximal inhibitory concentration 42-fold higher than the $C_{\text{max}}$ at the highest clinical dose. Brivaracetam 200mg/day may increase plasma concentrations of medicinal products transported by OAT3.

**Antiepileptic drugs**

Potential interactions between brivaracetam (50 mg/day to 200 mg/day) and other AEDs were investigated in a pooled analysis of plasma drug concentrations from all phase 2-3 studies in a population pharmacokinetic analysis of placebo-controlled phase 2-3 studies, and in dedicated drug-drug interaction studies (for the following AEDs: carbamazepine, lamotrigine, phenytoin and topiramate). The effect of the interactions on the plasma concentration is summarised in table 1 (increase is indicated as “↑” and decrease as “↓”, area under the plasma concentration versus time curve as “AUC”, maximum observed concentration as $C_{\text{max}}$).

**Table 1: Pharmacokinetic interactions between brivaracetam and other AEDs**

<table>
<thead>
<tr>
<th>AED coadministered</th>
<th>Influence of AED on brivaracetam plasma concentration</th>
<th>Influence of brivaracetam on AED plasma concentration</th>
</tr>
</thead>
</table>
| Carbamazepine      | AUC 29 % ↓  
$C_{\text{max}}$ 13 % ↓  
No dose adjustment required | Carbamazepine - None  
Carbamazepine-epoxide ↑  
(See below)  
No dose adjustment required. |
| Clobazam           | No data available | None |
| Clonazepam         | No data available | None |
| Lacosamide         | No data available | None |
| Lamotrigine        | None | None |
| Levetiracetam      | None | None |
| Oxcarbazepine      | None | None (monohydroxy derivative, MHD) |
| Phenobarbital      | AUC 19 % ↓  
No dose adjustment required | None |
| Phenytoin          | AUC 21 % ↓  
No dose adjustment required | None  
$^a$ AUC 20% ↑  
$^a$ $C_{\text{max}}$ 20% ↑ |
| Pregabalin         | No data available | None |
| Topiramate         | None | None |
| Valproic acid      | None | None |
| Zonisamide         | No data available | None |

$^a$ based on a study involving the administration of a supratherapeutic dose of 400 mg/day brivaracetam

**Carbamazepine**

Brivaracetam is a moderate reversible inhibitor of epoxide hydrolase resulting in an increased concentration of carbamazepine epoxide, an active metabolite of carbamazepine. In controlled studies, the carbamazepine epoxide plasma concentration increased by a mean of 37 %, 62 % and 98 % with little variability at brivaracetam doses of 50 mg/day, 100 mg/day and 200 mg/day respectively. No safety risks were observed. There was no additive effect of brivaracetam and valproate on the AUC of carbamazepine epoxide.

**Oral contraceptives**

Co-administration of brivaracetam (100 mg/day) with an oral contraceptive containing ethinylestradiol (0.03 mg) and levonorgestrel (0.15 mg) did not influence the pharmacokinetics of either substance. When brivaracetam was coadministered at a dose of 400 mg/day (twice the recommended maximum daily dose) with an oral contraceptive containing ethinylestradiol (0.03 mg) and levonorgestrel
(0.15 mg), a reduction in estrogen and progestin AUCs of 27 % and 23 %, respectively, was observed without impact on suppression of ovulation. There was generally no change in the concentration-time profiles of the endogenous markers estradiol, progesterone, luteinizing hormone (LH), follicle stimulating hormone (FSH), and sex hormone binding globulin (SHBG).

4.6 Fertility, pregnancy and lactation

Women of childbearing potential

Physicians should discuss family planning and contraception with women of childbearing potential taking brivaracetam (see Pregnancy). If a woman decides to become pregnant, the use of brivaracetam should be carefully re-evaluated.

Pregnancy

Risk related to epilepsy and antiepileptic medicinal products in general

For all anti-epileptic drugs, it has been shown that in the offspring of treated women with epilepsy, the prevalence of malformations is two to three times greater than the rate of approximately 3 % in the general population. In the treated population, an increase in malformations has been noted with polytherapy; however, the extent to which the treatment and/or the underlying condition is responsible has not been elucidated. Discontinuation of anti-epileptic treatments may result in exacerbation of the disease which could be harmful to the mother and the foetus.

Risk related to brivaracetam

There is a limited amount of data from the use of brivaracetam in pregnant women. There is no data on placental transfer in humans, but brivaracetam was shown to readily cross the placenta in rats (see section 5.3). The potential risk for humans is unknown. Animal studies did not detect any teratogenic potential of brivaracetam (see section 5.3).

In clinical studies, brivaracetam was used as adjunctive therapy and when it was used with carbamazepine, it induced a dose-related increase in the concentration of the active metabolite, carbamazepine-epoxide (see section 4.5). There is insufficient data to determine the clinical significance of this effect in pregnancy.

As a precautionary measure, brivaracetam should not be used during pregnancy unless clinically necessary i.e. (if the benefit to the mother clearly outweighs the potential risk to the foetus).

Breast-feeding

It is unknown whether brivaracetam is excreted in human breast milk. Studies in rats have shown excretion of brivaracetam in breast milk (see section 5.3). A decision should be made whether to discontinue breastfeeding or to discontinue brivaracetam, taking into account the benefit of the medicinal product to the mother. In case of co-administration of brivaracetam and carbamazepine, the amount of carbamazepine-epoxide excreted in breast milk could increase. There is insufficient data to determine the clinical significance.

Fertility

No human data on the effect of brivaracetam on fertility are available. In rats, there was no effect on fertility with brivaracetam (see section 5.3).

4.7 Effects on ability to drive and use machines

Brivaracetam has minor or moderate influence on the ability to drive and use machines.

Due to possible differences in individual sensitivity some patients might experience somnolence, dizziness, and other central nervous system (CNS) related symptoms. Patients should be advised not to
drive a car or to operate other potentially hazardous machines until they are familiar with the effects of brivaracetam on their ability to perform such activities.

4.8 Undesirable effects

Summary of the safety profile

In all controlled and uncontrolled trials in patients with epilepsy, 2,388 subjects have received brivaracetam, of whom 1,740 have been treated for ≥ 6 months, 1,363 for ≥ 12 months, 923 for ≥ 24 months and 569 for ≥ 60 months (5 years).

The most frequently reported adverse reactions (>10 %) with brivaracetam treatment were: somnolence (14.3 %) and dizziness (11.0 %). They were usually mild to moderate in intensity. Somnolence and fatigue (8.2 %) were reported at a higher incidence with increasing dose. The types of adverse reactions reported during the first 7 days of treatment were similar to those reported for the overall treatment period.

The discontinuation rate due to adverse reactions was 3.5 %, 3.4 % and 4.0 % for patients randomized to brivaracetam at respectively the dose of 50 mg/day, 100 mg/day and 200 mg/day and 1.7% for patients randomized to placebo. The adverse reactions most frequently resulting in discontinuation of brivaracetam therapy were dizziness (0.8 %) and convulsion (0.8 %).

Tabulated list of adverse reactions

In the table below, adverse reactions, which were identified based on review of the full brivaracetam clinical studies safety database, are listed by System Organ Class and frequency. The frequencies are defined as follows: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥ 1/1,000 to < 1/100). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

<table>
<thead>
<tr>
<th>System organ class</th>
<th>Frequency</th>
<th>Adverse reactions from clinical trials</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infections and infestations</td>
<td>Common</td>
<td>Influenza</td>
</tr>
<tr>
<td>Blood and lymphatic system disorders</td>
<td>Uncommon</td>
<td>Neutropenia</td>
</tr>
<tr>
<td>Metabolism and nutrition disorders</td>
<td>Common</td>
<td>Decreased appetite</td>
</tr>
<tr>
<td>Immune system disorders</td>
<td>Uncommon</td>
<td>Type I hypersensitivity</td>
</tr>
<tr>
<td>Psychiatric disorders</td>
<td>Common</td>
<td>Depression, anxiety, insomnia, irritability</td>
</tr>
<tr>
<td></td>
<td>Uncommon</td>
<td>Suicidal ideation, psychotic disorder, aggression, agitation</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>Very common</td>
<td>Dizziness, somnolence</td>
</tr>
<tr>
<td></td>
<td>Common</td>
<td>Convulsion, vertigo</td>
</tr>
<tr>
<td>Respiratory, thoracic and mediastinal disorders</td>
<td>Common</td>
<td>Upper respiratory tract infections, cough</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>Common</td>
<td>Nausea, vomiting, constipation</td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td>Common</td>
<td>Fatigue</td>
</tr>
</tbody>
</table>

Description of selected adverse reactions

Neutropenia has been reported in 0.5 % (6/1,099) brivaracetam patients and 0 % (0/459) placebo patients. Four of these subjects had decreased neutrophil counts at baseline, and experienced additional decrease in neutrophil counts after initiation of brivaracetam treatment. None of the 6 cases
of neutropenia were severe, required any specific treatment or led to discontinuation of brivaracetam and none had associated infections.

Suicidal ideation has been reported in 0.3 % (3/1,099) brivaracetam patients and 0.7 % (3/459) placebo patients. In the short-term clinical studies of brivaracetam in epilepsy patients, there were no cases of completed suicide and suicide attempt, however both have been reported in open-label extension studies (see section 4.4).

Reactions suggestive of immediate (Type I) hypersensitivity have been reported in a small number of brivaracetam patients (9/3022) during clinical development.

Open-label extension studies

In patients who were followed up in the open-label extension studies for up to 8 years, the safety profile was similar to that observed in the short-term, placebo-controlled studies.

Paediatric population

There are limited safety data from open-label studies in children from 1 month to <16 years of age. A total of 152 children (1 month to < 16 years of age) were treated with brivaracetam in a pharmacokinetic study and the related follow up study. From the limited available data, the most frequently reported TEAEs considered drug-related by the investigator were somnolence (10 %), decreased appetite (8 %), fatigue (5 %) and weight decreased (5 %). The safety profile appears to be consistent with that known in adults. No data are available on neurodevelopment. Currently, no clinical data are available in neonates.

Elderly

Of the 130 elderly subjects enrolled in the brivaracetam phase 2/3 development program (44 with epilepsy), 100 were 65-74 years of age and 30 were 75-84 years of age. The safety profile in elderly patients appears to be similar to that observed in younger adult patients.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

4.9 Overdose

Symptoms

There is limited clinical experience with brivaracetam overdose in humans. Somnolence and dizziness have been reported in a healthy subject taking a single dose of 1,400 mg of brivaracetam.

Management of overdose

There is no specific antidote for overdose with brivaracetam. Treatment of an overdose should include general supportive measures. Since less than 10 % of brivaracetam is excreted in urine, haemodialysis is not expected to significantly enhance brivaracetam clearance (see section 5.2).

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties
Pharmacotherapeutic group: antiepileptics, other antiepileptics, ATC code: N03AX23

Mechanism of action

Brivaracetam displays a high and selective affinity for synaptic vesicle protein 2A (SV2A), a transmembrane glycoprotein found at presynaptic level in neurons and in endocrine cells. Although the exact role of this protein remains to be elucidated it has been shown to modulate exocytosis of neurotransmitters. Binding to SV2A is believed to be the primary mechanism for brivaracetam anticonvulsant activity.

Clinical efficacy and safety

The efficacy of brivaracetam for the adjunctive therapy of partial-onset seizures (POS) was established in 3 randomized, double-blind, placebo-controlled, fixed-dose, multi-center studies in subjects 16 years of age and older. The daily dose of brivaracetam ranged from 5 to 200 mg/day across these studies. All studies had an 8-week baseline period followed by a 12-week treatment period with no up-titration. 1,558 patients received study drug of which 1,099 received brivaracetam. Study enrollment criteria required that patients have uncontrolled POS despite treatment with either 1 or 2 concomitant AEDs. Patients were required to have at least 8 POS during the baseline period. The primary endpoints in the phase 3 studies were the percent reduction in POS frequency over placebo and the 50 % responder rate based on 50 % reduction in POS frequency from baseline.

The most commonly taken AEDs at the time of study entry were carbamazepine (40.6 %), lamotrigine (25.2 %), valproate (20.5 %), oxcarbazepine (16.0 %), topiramate (13.5 %), phenytoin (10.2 %) and levetiracetam (9.8 %). The median baseline seizure frequency across the 3 studies was 9 seizures per 28 days. Patients had a mean duration of epilepsy of approximately 23 years. The efficacy outcomes are summarized in Table 2. Overall, brivaracetam was efficacious for the adjunctive treatment of partial onset seizures in patients 16 years of age and older between 50 mg/day and 200 mg/day.

Table 2: Key Efficacy Outcomes for Partial Onset Seizure Frequency per 28 Days

<table>
<thead>
<tr>
<th>Study</th>
<th>Placebo</th>
<th>Brivaracetam</th>
<th>* Statistically significant (p-value)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>50 mg/day</td>
<td>100 mg/day</td>
</tr>
<tr>
<td>Study N01253(1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>n= 96</td>
<td>n= 101</td>
<td></td>
<td></td>
</tr>
<tr>
<td>50 % Responder rate</td>
<td>16.7</td>
<td>32.7* (p=0.008)</td>
<td>~</td>
</tr>
<tr>
<td>Percent reduction over placebo (%)</td>
<td>NA</td>
<td>22.0* (p=0.0040)</td>
<td>~</td>
</tr>
<tr>
<td>Study N01252(2)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>n = 100</td>
<td>n = 99</td>
<td>n = 100</td>
<td></td>
</tr>
<tr>
<td>50 % Responder rate</td>
<td>20.0</td>
<td>27.3 (p=0.372)</td>
<td>36.0(2) (p=0.023)</td>
</tr>
<tr>
<td>Percent reduction over placebo (%)</td>
<td>NA</td>
<td>9.2 (p=0.0274)</td>
<td>20.5(2) (p=0.0097)</td>
</tr>
<tr>
<td>Study N01358</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>n = 259</td>
<td>n = 252</td>
<td>n = 249</td>
<td></td>
</tr>
<tr>
<td>50% Responder rate</td>
<td>21.6</td>
<td>~</td>
<td>38.9 (p=0.001)</td>
</tr>
<tr>
<td>Percent reduction over placebo (%)</td>
<td>NA</td>
<td>~</td>
<td>22.8* (p=0.001)</td>
</tr>
</tbody>
</table>

n = randomised patients who received at least 1 dose of study medication
~ Dose not studied
* Statistically significant
(1) Approximately 20 % of the patients were on concomitant levetiracetam
(2) The primary outcome for N01252 did not achieve statistical significance based on the sequential testing procedure. The 100 mg/day dose was nominally significant.
In clinical studies, a reduction in seizure frequency over placebo was higher with the dose of 100 mg/day than with 50 mg/day. Apart from dose-dependent increases in incidences of somnolence and fatigue brivaracetam 50 mg/day and 100 mg/day had a similar safety profile including CNS-related AEs and with long-term use.

Figure 1 shows the percentage of patients (excluding patients with concomitant levetiracetam) by category of reduction from baseline in POS frequency per 28 days in all 3 studies. Patients with more than a 25% increase in POS are shown at left as “worse”. Patients with an improvement in percent reduction in baseline POS frequency are shown in the 4 right-most categories. The percentages of patients with at least a 50% reduction in seizure frequency were 20.3%, 34.2%, 39.5%, and 37.8% for placebo, 50 mg/day, 100 mg/day, and 200 mg/day, respectively.

Figure 1: Proportion of patients by category of seizure response for brivaracetam and placebo over 12 weeks across all three double-blind pivotal trials

In a pooled analysis of the three pivotal trials, no differences in efficacy (measured as 50% responder rate) was observed within the dose range of 50 mg/day to 200 mg/day when brivaracetam is combined with inducing or non-inducing AEDs. In clinical studies 2.5% (4/161), 5.1% (17/332) and 4.0% (10/249) of the patients on brivaracetam 50 mg/day, 100 mg/day and 200 mg/day respectively became seizure free during the 12-week treatment period compared with 0.5% (2/418) on placebo.

Improvement in the median percent reduction in seizure frequency per 28 days has been observed in patients with type IC seizure (secondary generalized tonic-clonic seizures) at baseline treated with brivaracetam (66.6% (n=62), 61.2% (n=100) and 82.1% (n=75) of the patients on brivaracetam 50 mg/day, 100 mg/day and 200 mg/day respectively as compared to placebo 33.3% (n=115)).

The efficacy of brivaracetam in monotherapy has not been established. Brivaracetam is not recommended for use in monotherapy.

Treatment with levetiracetam

In two phase 3 randomised placebo-controlled studies, levetiracetam was administered as concomitant AED in about 20% of the patients. Although the number of subjects is limited, there was no observed benefit of brivaracetam versus placebo in patients taking levetiracetam concurrently which may reflect competition at the SV2A binding site. No additional safety or tolerability concerns were observed.
In a third study, a pre-specified analysis demonstrated efficacy over placebo for 100 mg/day and 200 mg/day in patients with prior exposure to levetiracetam. The lower efficacy observed in these patients compared to the levetiracetam-naïve patients was likely due to the higher number of prior AEDs used and higher baseline seizure frequency.

**Elderly (65 years of age and above)**
The three pivotal double-blind placebo-controlled studies included 38 elderly patients aged between 65 and 80 years. Although data are limited, the efficacy was comparable to younger subjects.

**Open label extension studies**
Across all studies, 81.7% of the patients who completed randomized studies were enrolled in the long-term open-label extension studies. From entry into the randomized studies, 5.3% of the subjects exposed to brivaracetam for 6 months (n=1,500) were seizure free compared to 4.6% and 3.7% for subjects exposed for 12 months (n=1,188) and 24 months (n=847), respectively. However, as a high proportion of subjects (26%) discontinued from the open-label studies due to lack of efficacy, a selection bias may have occurred, as the subjects who stayed in the study responded better than those who have terminated prematurely.

**Paediatric population**
The efficacy and tolerability of brivaracetam in paediatric patients have not been established (see section 4.2). Brivaracetam was evaluated in these patients in short term open-label pharmacokinetic study and an ongoing open-label extension study, in 152 subjects from 1 month to 16 years of age (see section 5.2).

The European Medicines Agency has deferred the obligation to submit the results of studies with brivaracetam in one or more subsets of the paediatric population in epilepsy with partial-onset seizures.

### 5.2 Pharmacokinetic properties

Brivaracetam film-coated tablets, oral solution and solution for intravenous injection show the same AUC, while the maximum plasma concentration is slightly higher after intravenous administration. Brivaracetam exhibits linear and time-independent pharmacokinetics with low intra- and inter-subject variability, and features complete absorption, very low protein binding, renal excretion following extensive biotransformation, and pharmacologically inactive metabolites.

#### Absorption

Brivaracetam is rapidly and completely absorbed after oral administration and the absolute bioavailability is approximately 100%. The median \( t_{\text{max}} \) for tablets taken without food is 1 hour (\( t_{\text{max}} \) range is 0.25 to 3 h). Coadministration with a high-fat meal slowed down the absorption rate (median \( t_{\text{max}} \) 3 h) and decreased the maximum plasma concentration (37% lower) of brivaracetam, while the extent of absorption remained unchanged.

#### Distribution

Brivaracetam is weakly bound (≤ 20 %) to plasma proteins. The volume of distribution is 0.5 L/kg, a value close to that of the total body water. Due to its lipophyllicity (Log P) brivaracetam has high cell membrane permeability.

#### Biotransformation

Brivaracetam is primarily metabolized by hydrolysis of the amide moiety to form the corresponding carboxylic acid (approximately 60% the elimination), and secondarily by hydroxylation on the propyl side chain (approximately 30% the elimination). The hydrolysis of the amide moiety leading to the
carboxylic acid metabolite (34 % of the dose in urine) is supported by hepatic and extra-hepatic amidase. In vitro, the hydroxylation of brivaracetam is mediated primarily by CYP2C19. Both metabolites, are further metabolised forming a common hydroxylated acid formed predominantly by hydroxylation of the propyl side chain on the carboxylic acid metabolite (mainly by CYP2C9). In vivo, in human subjects possessing ineffective mutations of CYP2C19, production of the hydroxy metabolite is decreased 10-fold while brivaracetam itself is increased by 22 % or 42 % in individuals with one or both mutated alleles. The three metabolites are not pharmacologically active.

Elimination

Brivaracetam is eliminated primarily by metabolism and by excretion in the urine. More than 95 % of the dose, including metabolites, is excreted in the urine within 72 hours after intake. Less than 1 % of the dose is excreted in faeces and less than 10 % of brivaracetam is excreted unchanged in urine. The terminal plasma half-life (t1/2) is approximately 9 hours. The total plasma clearance in patients was estimated to 3.6 L/h.

Linearity

Pharmacokinetics is dose-proportional from 10 to at least 600 mg.

Interactions with medicinal products

Brivaracetam is cleared by multiple pathways including renal excretion, non-CYP-mediated hydrolysis and CYP-mediated oxidations. In vitro, brivaracetam is not a substrate of human P-glycoprotein (P-gp), multidrug resistance proteins (MRP) 1 and 2, and likely not organic anion transporter polypeptide 1B1 (OATP1B1) and OATP1B3. In vitro assays showed that brivaracetam disposition should not be significantly affected by CYP (eg. CYP1A, 2C8, 2C9, 2D6 and 3A4) inhibitors.

In vitro, brivaracetam was not an inhibitor of the CYP1A2, 2A6, 2B6, 2C8, 2C9, 2D6, 3A4, or the transporters P-gp, BCRP, BSEP MRP2, MATE-K, MATE-1, OATP1B1, OATP1B3, OAT1 and OCT1 at clinically relevant concentrations. In vitro, brivaracetam did not induce CYP1A2.

Pharmacokinetics in special patient groups

Elderly (65 years of age and above)

In a study in elderly subjects (65 to 79 years old; with creatinine clearance 53 to 98 ml/min/1.73 m²) receiving brivaracetam 400 mg/day in bid administration, the plasma half-life of brivaracetam was 7.9 hours and 9.3 hours in the 65 to 75 and >75 years groups, respectively. The steady-state plasma clearance of brivaracetam was similar (0.76 ml/min/kg) to young healthy male subjects (0.83 ml/min/kg). (see section 4.2).

Renal impairment

A study in subjects with severe renal impairment (creatinine clearance <30 ml/min/1.73 m² and not requiring dialysis) revealed that the plasma AUC of brivaracetam was moderately increased (+21 %) relative to healthy controls, while the AUC of the acid, hydroxy and hydroxyacid metabolites were increased 3-, 4-, and 21-fold, respectively. The renal clearance of these non active metabolites was decreased 10-fold. The hydroxyacid metabolite did not reveal any safety concerns in non clinical studies. Brivaracetam has not been studied in patients undergoing hemodialysis (see section 4.2).

Hepatic impairment

A pharmacokinetic study in subjects with hepatic cirrhosis (Child-Pugh grades A, B, and C) showed similar increases in exposure to brivaracetam irrespective of disease severity (50 %, 57 % and 59 %), relative to matched healthy controls. (see section 4.2)

Paediatric population
In a pharmacokinetic study in 99 subjects aged 1 month to <16 years receiving brivaracetam oral solution, plasma concentrations were shown to be dose-proportional in all age groups. Population pharmacokinetics modeling indicated that the dose of 2.0 mg/kg twice a day provides the same steady-state average plasma concentration as in adults receiving 100 mg twice daily.

**Body weight**
A 40% decrease in steady-state plasma concentration has been estimated across a body weight range from 46 kg to 115 kg. However, this is not considered to be a clinically relevant difference.

**Gender**
There are no clinically relevant differences in the pharmacokinetics of brivaracetam by gender.

**Race**
The pharmacokinetics of brivaracetam was not significantly affected by race (Caucasian, Asian) in a population pharmacokinetic modeling from epilepsy patients. The number of patients with other ethnic background was limited.

**Pharmacokinetic/pharmacodynamics relationship**
The EC50 (brivaracetam plasma concentration corresponding to 50% of the maximum effect) was estimated to be 0.57 mg/L. This plasma concentration is slightly above the median exposure obtained after brivaracetam doses of 50 mg/day. Further seizure frequency reduction is obtained by increasing the dose to 100 mg/day and reaches a plateau at 200 mg/day.

5.3 Preclinical safety data

In safety pharmacology studies, the predominant effects were CNS related (mainly transient CNS depression and decreased spontaneous locomotor activity) seen at multiples (greater than 50 fold) of the pharmacologically active dose of brivaracetam, 2 mg/kg. Learning and memory function were not affected.

Findings not observed in clinical studies, but seen in the repeated-dose toxicology dog studies at exposure similar to the clinical plasma AUC, were hepatotoxic effects (mainly porphyria). However, toxicological data accumulated on brivaracetam and on a structurally-related compound indicate that the dog liver changes have developed through mechanisms not relevant for humans. No adverse liver changes were seen in rats and monkeys following chronic administration of brivaracetam at 5- and 42-fold the clinical AUC exposure. In monkeys, CNS signs (prostrate, loss of balance, clumsy movements) occurred at 64 fold the clinical Cmax, these effects being less apparent over time.

Genotoxicity studies have not detected any mutagenic or clastogenic activity. Carcinogenicity studies did not indicate any oncogenic potential in rats, whereas increased incidences of hepatocellular tumors in male mice are considered to result of a non-genotoxic, mode of action linked to a phenobarbitone-like liver enzyme induction, which is a known rodent specific phenomenon.

Brivaracetam did not affect male or female fertility and has demonstrated no teratogenic potential in either rat or rabbit. Embryotoxicity was observed in rabbits at a maternal toxic dose of brivaracetam with an exposure level 8-fold the clinical AUC exposure at the maximum recommended dose. In rats, brivaracetam was shown to readily cross the placenta and to be excreted in milk of lactating rats with concentrations similar to maternal plasma levels.

Brivaracetam did not show any dependence potential in rats.

**Juvenile animals studies**

In juvenile rats, brivaracetam exposure levels 6- to 15-fold the clinical AUC exposure at the maximum recommended dose induced developmental adverse effects (i.e. mortality, clinical signs, decreased body weight and lower brain weight). There were no adverse effects on CNS function, neuropathological and brain histopathological examination. In juvenile dogs, the brivaracetam-induced
changes at the exposure level 6-fold the clinical AUC were similar to those observed in adult animals. There were no adverse effects in any of the standard developmental or maturation endpoints.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

- Sodium citrate
- Citric acid anhydrous (for pH-adjustment)
- Methyl parahydroxybenzoate (E218)
- Carmellose sodium
- Sucralose
- Sorbitol liquid
- Glycerol (E422)
- Raspberry flavour (propylene glycol 90 % - 98 %)
- Purified water.

6.2 Incompatibilities

Not applicable

6.3 Shelf life

3 years.
After first opening: 5 months

6.4 Special precautions for storage

This medicinal product does not require any special storage conditions

6.5 Nature and contents of container

300 ml amber glass bottle (type III) with a white child resistant closure (polypropylene) in a box also containing a 10 ml graduated oral dosing syringe (polypropylene, polyethylene) and an adaptor for the syringe (polyethylene).

6.6 Special precautions for disposal

No special requirements.

Any unused medicinal product, neat or diluted, or waste material should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

UCB Pharma S.A.
Allée de la Recherche 60
B-1070 Bruxelles
Belgium

8. MARKETING AUTHORISATION NUMBER(S)

EU/1/15/1073/021
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 14 January 2016

10. DATE OF REVISION OF THE TEXT

Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

1. NAME OF THE MEDICINAL PRODUCT

Briviact 10 mg/ml solution for injection/infusion

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml contains 10mg brivaracetam
Each 5 ml vial contains 50 mg brivaracetam

Excipient(s) with known effect:
Each ml of solution for injection/infusion contains includes 3.8 mg sodium.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Solution for injection/infusion (injection/infusion)
Clear, colourless, solution.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Briviact is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy.

4.2 Posology and method of administration

Posology

Brivaracetam may be initiated with either intravenous or oral administration. When converting from oral to intravenous administration or vice versa, the total daily dose and frequency of administration should be maintained. Brivaracetam solution for injection/infusion is an alternative for patients when oral administration is temporarily not feasible.

The recommended starting dose is either 50 mg/day or 100 mg/day based on physician assessment of required seizure reduction versus potential side effects. The dose should be administered in two equally divided doses, once in the morning and once in the evening. Based on individual patient response and tolerability, the dose may be adjusted in the dose range of 50 mg/day to 200 mg/day.

There is no experience with twice daily intravenous administration of brivaracetam for a period longer than 4 days.

Missed doses

If patients missed one dose or more, it is recommended that they take a single dose as soon as they remember and take the following dose at the usual morning or evening time. This may avoid the brivaracetam plasma concentration falling below the efficacy level and prevent breakthrough seizures from occurring.
Discontinuation
If brivaracetam has to be discontinued it is recommended to withdraw it gradually by 50 mg/day on a weekly basis. After 1 week of treatment at 50 mg/day, a final week of treatment at the dose of 20 mg/day is recommended.

Special populations

Elderly (65 years of age and above)
No dose adjustment is needed in elderly patients (see section 5.2). The clinical experience in patients ≥ 65 years is limited.

Renal impairment
No dose adjustment is needed in patients with impaired renal function (see section 5.2). Brivaracetam is not recommended in end-stage renal disease patients undergoing dialysis due to lack of data.

Hepatic impairment
Exposure to brivaracetam was increased in patients with chronic liver disease. A 50 mg/day starting dose should be considered. A maximum daily dose of 150 mg administered in 2 divided doses is recommended for all stages of hepatic impairment (see sections 4.4 and 5.2).

Paediatric population
The safety and efficacy of brivaracetam in children aged less than 16 years have not yet been established. Currently available data are described in section 4.8, 5.1, and 5.2 but no recommendation on a posology can be made.

Method of administration

- Intravenous bolus: brivaracetam may be administered as an intravenous bolus without dilution.
- Intravenous infusion: brivaracetam may be diluted in a compatible diluent and administered as a 15-minute intravenous infusion (see section 6.6). This medicinal product must not be mixed with other medicinal products.

Brivaracetam bolus injection or intravenous infusion has not been studied in acute conditions; e.g. status epilepticus and is therefore not recommended for such conditions.

4.3 Contraindications

Hypersensitivity to the active substance or other pyrrolidone derivatives or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

Suicidal ideation and behaviour

Suicidal ideation and behaviour have been reported in patients treated with anti-epileptic drugs (AEDs), including brivaracetam, in several indications. A meta-analysis of randomized placebo-controlled trials of AEDs has also shown a small increased risk of suicidal ideation and behaviour. The mechanism of this risk is not known and the available data do not exclude the possibility of an increased risk for brivaracetam.

Patients should be monitored for signs of suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should any signs of suicidal ideation or behaviour emerge.
Hepatic impairment

There are limited clinical data on the use of brivaracetam in patients with pre-existing hepatic impairment. Dose adjustments are recommended for patients with hepatic impairment (see section 4.2).

Sodium content

The solution for injection/infusion contains 0.83 mmol (or 19.14 mg) sodium per vial. To be taken into consideration for patients on a controlled sodium diet.

4.5 Interaction with other medicinal products and other forms of interaction

Formal interaction studies have only been performed in adults.

Pharmacodynamic interactions

Concomitant treatment with levetiracetam

In the clinical studies, although the numbers were limited, there was no observed benefit of brivaracetam versus placebo in patients taking levetiracetam concurrently. No additional safety or tolerability concern was observed (see section 5.1).

Interaction with alcohol

In a pharmacokinetic and pharmacodynamic interaction study between brivaracetam 200 mg single dose and ethanol 0.6 g/L continuous infusion in healthy subjects, there was no pharmacokinetic interaction but brivaracetam approximately doubled the effect of alcohol on psychomotor function, attention and memory. Intake of brivaracetam with alcohol is not recommended.

Pharmacokinetic interactions

Effects of other agents on the pharmacokinetics of brivaracetam

In vitro data suggest that brivaracetam has a low interaction potential. The main disposition pathway of brivaracetam is by CYP-independent hydrolysis. A second disposition pathway involves hydroxylation mediated by CYP2C19 (see section 5.2).

Brivaracetam plasma concentrations may increase when coadministered with CYP2C19 strong inhibitors (e.g. fluconazole, fluvoxamine), but the risk of a clinically relevant CYP2C19-mediated interaction is considered to be low.

Rifampicin

In healthy subjects, coadministration with the strong enzyme inducer rifampicin (600 mg/day for 5 days), decreased brivaracetam area under the plasma concentration curve (AUC) by 45 %. Prescribers should consider adjusting the brivaracetam dose in patients starting or ending treatment with rifampicin.

Strong enzyme inducing AEDs

Brivaracetam plasma concentrations are decreased when coadministered with strong enzyme inducing AEDs (carbamazepine, phenobarbital, phenytoin) but no dose adjustment is required (see table 1).

Other enzyme inducers

Other strong enzyme inducers (such as St John’s wort (Hypericum perforatum)) may also decrease the systemic exposure of brivaracetam. Therefore, starting or ending treatment with St John’s wort should be done with caution.

Effects of brivaracetam on other medicinal products

Brivaracetam given 50 or 150 mg/day did not affect the AUC of midazolam (metabolised by CYP3A4). The risk of clinically relevant CYP3A4 interactions is considered to be low.
**In vitro** studies have shown that brivaracetam exhibits little or no inhibition of CYP450 isoforms except for CYP2C19. Brivaracetam may increase plasma concentrations of medicinal products metabolised by CYP2C19 (e.g. lanzoprazole, omeprazole, diazepam). When tested **in vitro** brivaracetam did not induce CYP1A1/2 but induced CYP3A4 and CYP2B6. No CYP3A4 induction was found **in vivo** (see midazolam above). CYP2B6 induction has not been investigated **in vivo** and brivaracetam may decrease plasma concentrations of medicinal products metabolised by CYP2B6 (e.g. efavirenz). In vitro, interaction studies to determine the potential inhibitory effects on transporters concluded that there were no clinically relevant effects, except for OAT3. **In vitro**, brivaracetam inhibits OAT3 with a half maximal inhibitory concentration 42-fold higher than the Cmax at the highest clinical dose. Brivaracetam 200mg/day may increase plasma concentrations of medicinal products transported by OAT3.

**Antiepileptic drugs**

Potential interactions between brivaracetam (50 mg/day to 200 mg/day) and other AEDs were investigated in a pooled analysis of plasma drug concentrations from all phase 2-3 studies in a population pharmacokinetic analysis of placebo-controlled phase 2-3 studies, and in dedicated drug-drug interaction studies (for the following AEDs: carbamazepine, lamotrigine, phenytoin and topiramate). The effect of the interactions on the plasma concentration is summarised in table 1 (increase is indicated as “↑” and decrease as “↓”, area under the plasma concentration versus time curve as “AUC”, maximum observed concentration as Cmax).

**Table 1: Pharmacokinetic interactions between brivaracetam and other AEDs**

<table>
<thead>
<tr>
<th>AED coadministered</th>
<th>Influence of AED on brivaracetam plasma concentration</th>
<th>Influence of brivaracetam on AED plasma concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carbamazepine</td>
<td>AUC 29 % ↓ Cmax 13 % ↓ No dose adjustment required</td>
<td>Carbamazepine - None Carbamazepine-epoxide ↑ (See below) No dose adjustment required.</td>
</tr>
<tr>
<td>Clobazam</td>
<td>No data available</td>
<td>None</td>
</tr>
<tr>
<td>Clonazepam</td>
<td>No data available</td>
<td>None</td>
</tr>
<tr>
<td>Lacosamide</td>
<td>No data available</td>
<td>None</td>
</tr>
<tr>
<td>Lamotrigine</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Levetiracetam</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Oxcarbazepine</td>
<td>None</td>
<td>None (monohydroxy derivative, MHD)</td>
</tr>
<tr>
<td>Phenobarbital</td>
<td>AUC 19 % ↓ No dose adjustment required</td>
<td>None</td>
</tr>
<tr>
<td>Phenytoin</td>
<td>AUC 21 % ↓ No dose adjustment required</td>
<td>None a AUC 20% ↑ a Cmax 20% ↑</td>
</tr>
<tr>
<td>Pregabalin</td>
<td>No data available</td>
<td>None</td>
</tr>
<tr>
<td>Topiramate</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Valproic acid</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Zonisamide</td>
<td>No data available</td>
<td>None</td>
</tr>
</tbody>
</table>

*based on a study involving the administration of a supratherapeutic dose of 400 mg/day brivaracetam

**Carbamazepine**

Brivaracetam is a moderate reversible inhibitor of epoxide hydrolase resulting in an increased concentration of carbamazepine epoxide, an active metabolite of carbamazepine. In controlled studies, the carbamazepine epoxide plasma concentration increased by a mean of 37 %, 62 % and 98 % with little variability at brivaracetam doses of 50 mg/day, 100 mg/day and 200 mg/day respectively. No safety risks were observed. There was no additive effect of brivaracetam and valproate on the AUC of carbamazepine epoxide.
Oral contraceptives

Co-administration of brivaracetam (100 mg/day) with an oral contraceptive containing ethinylestradiol (0.03 mg) and levonorgestrel (0.15 mg) did not influence the pharmacokinetics of either substance. When brivaracetam was coadministered at a dose of 400 mg/day (twice the recommended maximum daily dose) with an oral contraceptive containing ethinylestradiol (0.03 mg) and levonorgestrel (0.15 mg), a reduction in estrogen and progestin AUCs of 27 % and 23 %, respectively, was observed without impact on suppression of ovulation. There was generally no change in the concentration-time profiles of the endogenous markers estradiol, progesterone, luteinizing hormone (LH), follicle stimulating hormone (FSH), and sex hormone binding globulin (SHBG).

4.6 Fertility, pregnancy and lactation

Women of childbearing potential

Physicians should discuss family planning and contraception with women of childbearing potential taking brivaracetam (see Pregnancy).

If a woman decides to become pregnant, the use of brivaracetam should be carefully re-evaluated.

Pregnancy

Risk related to epilepsy and antiepileptic medicinal products in general

For all anti-epileptic drugs, it has been shown that in the offspring of treated women with epilepsy, the prevalence of malformations is two to three times greater than the rate of approximately 3 % in the general population. In the treated population, an increase in malformations has been noted with polytherapy; however, the extent to which the treatment and/or the underlying condition is responsible has not been elucidated. Discontinuation of anti-epileptic treatments may result in exacerbation of the disease which could be harmful to the mother and the foetus.

Risk related to brivaracetam

There is a limited amount of data from the use of brivaracetam in pregnant women. There is no data on placental transfer in humans, but brivaracetam was shown to readily cross the placenta in rats (see section 5.3). The potential risk for humans is unknown. Animal studies did not detect any teratogenic potential of brivaracetam (see section 5.3).

In clinical studies, brivaracetam was used as adjunctive therapy and when it was used with carbamazepine, it induced a dose-related increase in the concentration of the active metabolite, carbamazepine-epoxide (see section 4.5). There is insufficient data to determine the clinical significance of this effect in pregnancy.

As a precautionary measure, brivaracetam should not be used during pregnancy unless clinically necessary i.e. (if the benefit to the mother clearly outweighs the potential risk to the foetus).

Breast-feeding

It is unknown whether brivaracetam is excreted in human breast milk. Studies in rats have shown excretion of brivaracetam in breast milk (see section 5.3). A decision should be made whether to discontinue breastfeeding or to discontinue brivaracetam, taking into account the benefit of the medicinal product to the mother. In case of co-administration of brivaracetam and carbamazepine, the amount of carbamazepine-epoxide excreted in breast milk could increase. There is insufficient data to determine the clinical significance.

Fertility

No human data on the effect of brivaracetam on fertility are available. In rats, there was no effect on fertility with brivaracetam (see section 5.3).
4.7 Effects on ability to drive and use machines

Brivaracetam has minor or moderate influence on the ability to drive and use machines.

Due to possible differences in individual sensitivity some patients might experience somnolence, dizziness, and other central nervous system (CNS) related symptoms. Patients should be advised not to drive a car or to operate other potentially hazardous machines until they are familiar with the effects of brivaracetam on their ability to perform such activities.

4.8 Undesirable effects

Summary of the safety profile

In all controlled and uncontrolled trials in patients with epilepsy, 2,388 subjects have received brivaracetam, of whom 1,740 have been treated for ≥ 6 months, 1,363 for ≥ 12 months, 923 for ≥ 24 months and 569 for ≥ 60 months (5 years).

The most frequently reported adverse reactions (>10%) with brivaracetam treatment were: somnolence (14.3 %) and dizziness (11.0 %). They were usually mild to moderate in intensity. Somnolence and fatigue (8.2 %) were reported at a higher incidence with increasing dose. The types of adverse reactions reported during the first 7 days of treatment were similar to those reported for the overall treatment period.

The discontinuation rate due to adverse reactions was 3.5 %, 3.4 % and 4.0 % for patients randomized to brivaracetam at respectively the dose of 50 mg/day, 100 mg/day and 200 mg/day and 1.7 % for patients randomized to placebo. The adverse reactions most frequently resulting in discontinuation of brivaracetam therapy were dizziness (0.8 %) and convulsion (0.8 %).

Tabulated list of adverse reactions

In the table below, adverse reactions, which were identified based on review of the full brivaracetam clinical studies safety database, are listed by System Organ Class and frequency. The frequencies are defined as follows: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥ 1/1,000 to < 1/100). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

<table>
<thead>
<tr>
<th>System organ class</th>
<th>Frequency</th>
<th>Adverse reactions from clinical trials</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infections and infestations</td>
<td>Common</td>
<td>Influenza</td>
</tr>
<tr>
<td>Blood and lymphatic system disorders</td>
<td>Uncommon</td>
<td>Neutropenia</td>
</tr>
<tr>
<td>Metabolism and nutrition disorders</td>
<td>Common</td>
<td>Decreased appetite</td>
</tr>
<tr>
<td>Immune system disorders</td>
<td>Uncommon</td>
<td>Type I hypersensitivity</td>
</tr>
<tr>
<td>Psychiatric disorders</td>
<td>Common</td>
<td>Depression, anxiety, insomnia, irritability</td>
</tr>
<tr>
<td></td>
<td>Uncommon</td>
<td>Suicidal ideation, psychotic disorder, aggression, agitation</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>Very common</td>
<td>Dizziness, somnolence</td>
</tr>
<tr>
<td></td>
<td>Common</td>
<td>Convulsion, vertigo</td>
</tr>
<tr>
<td>Respiratory, thoracic and mediastinal disorders</td>
<td>Common</td>
<td>Upper respiratory tract infections, cough</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>Common</td>
<td>Nausea, vomiting, constipation</td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td>Common</td>
<td>Fatigue</td>
</tr>
</tbody>
</table>
Description of selected adverse reactions

Neutropenia has been reported in 0.5% (6/1,099) brivaracetam patients and 0% (0/459) placebo patients. Four of these subjects had decreased neutrophil counts at baseline, and experienced additional decrease in neutrophil counts after initiation of brivaracetam treatment. None of the 6 cases of neutropenia were severe, required any specific treatment or led to discontinuation of brivaracetam and none had associated infections.

Suicidal ideation has been reported in 0.3% (3/1,099) brivaracetam patients and 0.7% (3/459) placebo patients. In the short-term clinical studies of brivaracetam in epilepsy patients, there were no cases of completed suicide and suicide attempt, however both have been reported in open-label extension studies (see section 4.4).

Reactions suggestive of immediate (Type I) hypersensitivity have been reported in a small number of brivaracetam patients (9/3022) during clinical development.

Adverse reactions with intravenous administration generally appeared to be similar to those observed with oral administration. Intravenous administration was associated with infusion site pain in 2.8% of the patients.

Open-label extension studies

In patients who were followed up in the open-label extension studies for up to 8 years, the safety profile was similar to that observed in the short-term, placebo-controlled studies.

Paediatric population

There are limited safety data from open-label studies in children from 1 month to <16 years of age. A total of 152 children (1 month to <16 years of age) were treated with brivaracetam in a pharmacokinetic study and the related follow-up study. From the limited available data, the most frequently reported TEAEs considered drug-related by the investigator were somnolence (10%), decreased appetite (8%), fatigue (5%) and weight decreased (5%). The safety profile appears to be consistent with that known in adults. No data are available on neurodevelopment. Currently, no clinical data are available in neonates.

Elderly

Of the 130 elderly subjects enrolled in the brivaracetam phase 2/3 development program (44 with epilepsy), 100 were 65-74 years of age and 30 were 75-84 years of age. The safety profile in elderly patients appears to be similar to that observed in younger adult patients.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

4.9 Overdose

Symptoms

There is limited clinical experience with brivaracetam overdose in humans. Somnolence and dizziness have been reported in a healthy subject taking a single dose of 1,400 mg of brivaracetam.

Management of overdose
There is no specific antidote for overdose with brivaracetam. Treatment of an overdose should include general supportive measures. Since less than 10 % of brivaracetam is excreted in urine, haemodialysis is not expected to significantly enhance brivaracetam clearance (see section 5.2).

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: antiepileptics, other antiepileptics, ATC code: N03AX23

Mechanism of action

Brivaracetam displays a high and selective affinity for synaptic vesicle protein 2A (SV2A), a transmembrane glycoprotein found at presynaptic level in neurons and in endocrine cells. Although the exact role of this protein remains to be elucidated it has been shown to modulate exocytosis of neurotransmitters. Binding to SV2A is believed to be the primary mechanism for brivaracetam anticonvulsant activity.

Clinical efficacy and safety

The efficacy of brivaracetam for the adjunctive therapy of partial-onset seizures (POS) was established in 3 randomized, double-blind, placebo-controlled, fixed-dose, multi-center studies in subjects 16 years of age and older. The daily dose of brivaracetam ranged from 5 to 200 mg/day across these studies. All studies had an 8-week baseline period followed by a 12-week treatment period with no up-titration. 1,558 patients received study drug of which 1,099 received brivaracetam. Study enrollment criteria required that patients have uncontrolled POS despite treatment with either 1 or 2 concomitant AEDs. Patients were required to have at least 8 POS during the baseline period. The primary endpoints in the phase 3 studies were the percent reduction in POS frequency over placebo and the 50 % responder rate based on 50 % reduction in POS frequency from baseline.

The most commonly taken AEDs at the time of study entry were carbamazepine (40.6 %), lamotrigine (25.2 %), valproate (20.5 %), oxcarbazepine (16.0 %), topiramate (13.5 %), phenytoin (10.2 %) and levetiracetam (9.8 %). The median baseline seizure frequency across the 3 studies was 9 seizures per 28 days. Patients had a mean duration of epilepsy of approximately 23 years.

The efficacy outcomes are summarized in Table 2. Overall, brivaracetam was efficacious for the adjunctive treatment of partial onset seizures in patients 16 years of age and older between 50 mg/day and 200 mg/day.

<table>
<thead>
<tr>
<th>Study</th>
<th>Placebo</th>
<th>Brivaracetam</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>50 mg/day</td>
<td>100 mg/day</td>
</tr>
<tr>
<td>Study N01253(1)</td>
<td>n= 96</td>
<td>n= 101</td>
</tr>
<tr>
<td>50 % Responder rate</td>
<td>16.7</td>
<td>32.7*(p=0.008)</td>
</tr>
<tr>
<td>Percent reduction over placebo (%)</td>
<td>NA</td>
<td>22.0*(p=0.0040)</td>
</tr>
<tr>
<td>Study N01252(1)</td>
<td>n = 100</td>
<td>n = 99</td>
</tr>
<tr>
<td>50 % Responder rate</td>
<td>20.0</td>
<td>27.3*(p=0.372)</td>
</tr>
<tr>
<td>Percent reduction over placebo (%)</td>
<td>NA</td>
<td>9.2*(p=0.0274)</td>
</tr>
<tr>
<td>Study</td>
<td>Placebo</td>
<td>Brivaracetam</td>
</tr>
<tr>
<td>-------------</td>
<td>---------</td>
<td>--------------</td>
</tr>
<tr>
<td></td>
<td>n = 259</td>
<td>n = 252</td>
</tr>
<tr>
<td>50% Responder rate</td>
<td>21.6</td>
<td>38.9* (p&lt;0.001)</td>
</tr>
<tr>
<td>Percent reduction over placebo (%)</td>
<td>NA</td>
<td>22.8* (p&lt;0.001)</td>
</tr>
</tbody>
</table>

n = randomised patients who received at least 1 dose of study medication

~ Dose not studied

* Statistically significant

(1) Approximately 20 % of the patients were on concomitant levetiracetam

(2) The primary outcome for N01252 did not achieve statistical significance based on the sequential testing procedure, The 100 mg/day dose was nominally significant.

In clinical studies, a reduction in seizure frequency over placebo was higher with the dose of 100 mg/day than with 50 mg/day. Apart from dose-dependent increases in incidences of somnolence and fatigue brivaracetam 50 mg/day and 100 mg/day had a similar safety profile including CNS-related AEs and with long-term use.

Figure 1 shows the percentage of patients (excluding patients with concomitant levetiracetam) by category of reduction from baseline in POS frequency per 28 days in all 3 studies. Patients with more than a 25 % increase in POS are shown at left as “worse”. Patients with an improvement in percent reduction in baseline POS frequency are shown in the 4 right-most categories. The percentages of patients with at least a 50 % reduction in seizure frequency were 20.3 %, 34.2 %, 39.5 %, and 37.8 % for placebo, 50 mg/day, 100 mg/day, and 200 mg/day, respectively.

Figure 1: Proportion of patients by category of seizure response for brivaracetam and placebo over 12 weeks across all three double-blind pivotal trials

In a pooled analysis of the three pivotal trials, no differences in efficacy (measured as 50 % responder rate) was observed within the dose range of 50 mg/day to 200 mg/day when brivaracetam is combined with inducing or non-inducing AEDs. In clinical studies 2.5 % (4/161), 5.1 % (17/332) and 4.0% (10/249) of the patients on brivaracetam 50 mg/day, 100 mg/day and 200 mg/day respectively became seizure free during the 12-week treatment period compared with 0.5 % (2/418) on placebo.
Improvement in the median percent reduction in seizure frequency per 28 days has been observed in patients with type IC seizure (secondary generalized tonic-clonic seizures) at baseline treated with brivaracetam (66.6 % (n=62), 61.2 % (n=100) and 82.1 % (n=75) of the patients on brivaracetam 50 mg/day, 100 mg/day and 200 mg/day respectively as compared to placebo 33.3 % (n=115)).

The efficacy of brivaracetam in monotherapy has not been established. Brivaracetam is not recommended for use in monotherapy.

Treatment with levetiracetam

In two phase 3 randomised placebo-controlled studies, levetiracetam was administered as concomitant AED in about 20 % of the patients. Although the number of subjects is limited, there was no observed benefit of brivaracetam versus placebo in patients taking levetiracetam concurrently which may reflect competition at the SV2A binding site. No additional safety or tolerability concerns were observed.

In a third study, a pre-specified analysis demonstrated efficacy over placebo for 100 mg/day and 200 mg/day in patients with prior exposure to levetiracetam. The lower efficacy observed in these patients compared to the levetiracetam-naïve patients was likely due to the higher number of prior AEDs used and higher baseline seizure frequency.

Elderly (65 years of age and above)
The three pivotal double-blind placebo-controlled studies included 38 elderly patients aged between 65 and 80 years. Although data are limited, the efficacy was comparable to younger subjects.

Open label extension studies
Across all studies, 81.7 % of the patients who completed randomized studies were enrolled in the long-term open-label extension studies. From entry into the randomized studies, 5.3 % of the subjects exposed to brivaracetam for 6 months (n=1,500) were seizure free compared to 4.6 % and 3.7 % for subjects exposed for 12 months (n=1,188) and 24 months (n=847), respectively. However, as a high proportion of subjects (26%) discontinued from the open-label studies due to lack of efficacy, a selection bias may have occurred, as the subjects who stayed in the study responded better than those who have terminated prematurely.

Paediatric population

The efficacy and tolerability of brivaracetam in paediatric patients have not been established (see section 4.2). Brivaracetam was evaluated in these patients in short term open label pharmacokinetic study and an ongoing open-label extension study, in 152 subjects from 1 month to 16 years of age (see section 5.2).

The European Medicines Agency has deferred the obligation to submit the results of studies with brivaracetam in one or more subsets of the paediatric population in epilepsy with partial onset seizures.

5.2 Pharmacokinetic properties

Brivaracetam film-coated tablets, oral solution and solution for intravenous injection show the same AUC, while the maximum plasma concentration is slightly higher after intravenous administration. Brivaracetam exhibits linear and time-independent pharmacokinetics with low intra- and inter-subject variability, and features complete absorption, very low protein binding, renal excretion following extensive biotransformation, and pharmacologically inactive metabolites.

Absorption

Brivaracetam is rapidly and completely absorbed after oral administration and the absolute bioavailability is approximately 100 %. The median t_{max} for tablets taken without food is 1 hour (t_{max} range is 0.25 to 3 h).
Coadministration with a high-fat meal slowed down the absorption rate (median $t_{\text{max}}$ 3 h) and decreased the maximum plasma concentration (37 % lower) of brivaracetam, while the extent of absorption remained unchanged.

**Distribution**

Brivaracetam is weakly bound ($\leq 20 \%$) to plasma proteins. The volume of distribution is 0.5 L/kg, a value close to that of the total body water.

Due to its lipophylicity (Log P) brivaracetam has high cell membrane permeability.

**Biotransformation**

Brivaracetam is primarily metabolized by hydrolysis of the amide moiety to form the corresponding carboxylic acid (approximately 60 % the elimination), and secondarily by hydroxylation on the propyl side chain (approximately 30 % the elimination). The hydrolysis of the amide moiety leading to the carboxylic acid metabolite (34 % of the dose in urine) is supported by hepatic and extra-hepatic amidase. *In vitro*, the hydroxylation of brivaracetam is mediated primarily by CYP2C19. Both metabolites, are further metabolised forming a common hydroxylated acid formed predominantly by hydroxylation of the propyl side chain on the carboxylic acid metabolite (mainly by CYP2C9). *In vivo*, in human subjects possessing ineffective mutations of CYP2C19, production of the hydroxy metabolite is decreased 10-fold while brivaracetam itself is increased by 22 % or 42 % in individuals with one or both mutated alleles. The three metabolites are not pharmacologically active.

**Elimination**

Brivaracetam is eliminated primarily by metabolism and by excretion in the urine. More than 95 % of the dose, including metabolites, is excreted in the urine within 72 hours after intake. Less than 1 % of the dose is excreted in faeces and less than 10 % of brivaracetam is excreted unchanged in urine. The terminal plasma half-life ($t_{1/2}$) is approximately 9 hours. The total plasma clearance in patients was estimated to 3.6 L/h.

**Linearity**

Pharmacokinetics is dose-proportional from 10 to at least 600 mg.

**Interactions with medicinal products**

Brivaracetam is cleared by multiple pathways including renal excretion, non-CYP-mediated hydrolysis and CYP-mediated oxidations. *In vitro*, brivaracetam is not a substrate of human P-glycoprotein (P-gp), multidrug resistance proteins (MRP) 1 and 2, and likely not organic anion transporter polypeptide 1B1 (OATP1B1) and OATP1B3.

*In vitro* assays showed that brivaracetam disposition should not be significantly affected by CYP (eg. CYP1A2, 2C8, 2C9, 2D6 and 3A4) inhibitors.

In vitro, brivaracetam was not an inhibitor of the CYP1A2, 2A6, 2B6, 2C8, 2C9, 2D6, 3A4, or the transporters P-gp, BCRP, BSEP MRP2, MATE-K, MATE-1, OATP1B1, OATP1B3, OAT1 and OCT1 at clinically relevant concentrations. In vitro, brivaracetam did not induce CYP1A2.

**Pharmacokinetics in special patient groups**

*Elderly (65 years of age and above)*

In a study in elderly subjects (65 to 79 years old; with creatinine clearance 53 to 98 ml/min/1.73 m²) receiving brivaracetam 400 mg/day in bid administration, the plasma half-life of brivaracetam was 7.9 hours and 9.3 hours in the 65 to 75 and >75 years groups, respectively. The steady-state plasma clearance of brivaracetam was similar (0.76 ml/min/kg) to young healthy male subjects (0.83 ml/min/kg). (see section 4.2).
Renal impairment
A study in subjects with severe renal impairment (creatinine clearance <30 ml/min/1.73 m² and not requiring dialysis) revealed that the plasma AUC of brivaracetam was moderately increased (+21 %) relative to healthy controls, while the AUC of the acid, hydroxy and hydroxyacid metabolites were increased 3-, 4-, and 21-fold, respectively. The renal clearance of these non active metabolites was decreased 10-fold. The hydroxyacid metabolite did not reveal any safety concerns in non clinical studies. Brivaracetam has not been studied in patients undergoing hemodialysis (see section 4.2).

Hepatic impairment
A pharmacokinetic study in subjects with hepatic cirrhosis (Child-Pugh grades A, B, and C) showed similar increases in exposure to brivaracetam irrespective of disease severity (50 %, 57 % and 59 %), relative to matched healthy controls. (see section 4.2)

Paediatric population
In a pharmacokinetic study in 99 subjects aged 1 month to <16 years receiving brivaracetam oral solution, plasma concentrations were shown to be dose-proportional in all age groups. Population pharmacokinetics modeling indicated that the dose of 2.0 mg/kg twice a day provides the same steady-state average plasma concentration as in adults receiving 100 mg twice daily.

Body weight
A 40 % decrease in steady-state plasma concentration has been estimated across a body weight range from 46 kg to 115 kg. However, this is not considered to be a clinically relevant difference.

Gender
There are no clinically relevant differences in the pharmacokinetics of brivaracetam by gender.

Race
The pharmacokinetics of brivaracetam was not significantly affected by race (Caucasian, Asian) in a population pharmacokinetic modeling from epilepsy patients. The number of patients with other ethnic background was limited.

Pharmacokinetic/pharmacodynamics relationship
The EC50 (brivaracetam plasma concentration corresponding to 50 % of the maximum effect) was estimated to be 0.57 mg/L. This plasma concentration is slightly above the median exposure obtained after brivaracetam doses of 50 mg/day. Further seizure frequency reduction is obtained by increasing the dose to 100 mg/day and reaches a plateau at 200 mg/day.

5.3 Preclinical safety data
In safety pharmacology studies, the predominant effects were CNS related (mainly transient CNS depression and decreased spontaneous locomotor activity) seen at multiples (greater than 50 fold) of the pharmacologically active dose of brivaracetam, 2 mg/kg. Learning and memory function were not affected.

Findings not observed in clinical studies, but seen in the repeated-dose toxicology dog studies at exposure similar to the clinical plasma AUC, were hepatotoxic effects (mainly porphyria). However, toxicological data accumulated on brivaracetam and on a structurally-related compound indicate that the dog liver changes have developed through mechanisms not relevant for humans. No adverse liver changes were seen in rats and monkeys following chronic administration of brivaracetam at 5- and 42-fold the clinical AUC exposure. In monkeys, CNS signs (prostrate, loss of balance, clumsy movements) occurred at 64 fold the clinical Cmax, these effects being less apparent over time.

Genotoxicity studies have not detected any mutagenic or clastogenic activity. Carcinogenicity studies did not indicate any oncogenic potential in rats, whereas increased incidences of hepatocellular tumors in male mice are considered to result of a non-genotoxic, mode of action linked to a phenobarbitone-like liver enzyme induction, which is a known rodent specific phenomenon.
Brivaracetam did not affect male or female fertility and has demonstrated no teratogenic potential in either rat or rabbit. Embryotoxicity was observed in rabbits at a maternal toxic dose of brivaracetam with an exposure level 8-fold the clinical AUC exposure at the maximum recommended dose. In rats, brivaracetam was shown to readily cross the placenta and to be excreted in milk of lactating rats with concentrations similar to maternal plasma levels.

Brivaracetam did not show any dependence potential in rats.

**Juvenile animals studies**

In juvenile rats, brivaracetam exposure levels 6- to 15-fold the clinical AUC exposure at the maximum recommended dose induced developmental adverse effects (i.e. mortality, clinical signs, decreased body weight and lower brain weight). There were no adverse effects on CNS function, neuropathological and brain histopathological examination. In juvenile dogs, the brivaracetam-induced changes at the exposure level 6- fold the clinical AUC were similar to those observed in adult animals. There were no adverse effects in any of the standard developmental or maturation endpoints.

6. **PHARMACEUTICAL PARTICULARS**

6.1 **List of excipients**

Sodium acetate (trihydrate)
Acetic acid, glacial (for pH-adjustment)
Sodium chloride
Water for injections

6.2 **Incompatibilities**

This medicinal product must not be mixed with other medicinal products.

6.3 **Shelf life**

3 years.
Following dilution, brivaracetam solution for injection/infusion was found to be physically compatible and chemically stable when mixed with the diluents listed in the section 6.6 for 24 hours and stored in PVC or polyolefin bags at temperature up to 25°C. From a microbiological point of view, the product should be used immediately after dilution. If not used immediately, in-use storage time and conditions prior to use are the responsibility of the user.

6.4 **Special precautions for storage**

This medicinal product does not require any special storage conditions.

For storage conditions after dilution of the medicinal product, see section 6.3.

6.5 **Nature and contents of container**

10 mg/ml solution for injection/infusion is packed in 6 ml nominal capacity glass vials (type I) with siliconized bromobutyl rubber stoppers and sealed with an aluminium/polypropylene tear off cap. Each single use vial contains an extractable volume of not less than 5.0 ml of solution for injection/infusion.

Each carton contains 10 vials.

6.6 **Special precautions for disposal and other handling**
This medicinal product is for single use only, any unused solution should be discarded. Product with particulate matter or discoloration should not be used. Brivaracetam solution for injection/infusion is physically compatible and chemically stable when mixed with the following diluents:

Diluents:
- Sodium chloride 9 mg/ml (0.9 %) solution for injection
- Glucose 50 mg/ml (5 %) solution for injection
- Lactated Ringer’s solution for injection.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

UCB Pharma S.A.
Allée de la Recherche 60
B-1070 Bruxelles
Belgium

8. MARKETING AUTHORISATION NUMBER(S)

EU/1/15/1073/022

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 14 January 2016

10. DATE OF REVISION OF THE TEXT

ANNEX II

A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer(s) responsible for batch release

UCB Pharma S.A.
Chemin du Foriest
B-1420 Braine l'Alleud
Belgium

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to medical prescription.

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

- Periodic safety update reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

The marketing authorisation holder shall submit the first periodic safety update report for this product within 6 months following authorisation.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

- Risk Management Plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;

- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.
ANNEX III

LABELLING AND PACKAGE LEAFLET
A. LABELLING
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON

1. NAME OF THE MEDICINAL PRODUCT

Briviact 10 mg film-coated tablets
brivaracetam

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each film-coated tablet contains 10 mg brivaracetam.

3. LIST OF EXCIPIENTS

Contains croscarmellose sodium, lactose monohydrate and lactose anhydrous.
See leaflet for further information. (Omitted from cartons of 14 film-coated tablets)

4. PHARMACEUTICAL FORM AND CONTENTS

14 film-coated tablets
56 film-coated tablets
100 x 1 film-coated tablet
14 x 1 film-coated tablet

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
Oral use

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

UCB Pharma S.A.
Allée de la Recherche 60
B-1070 Brussels
Belgium

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/15/1073/001 14 film-coated tablets
EU/1/15/1073/002 56 film-coated tablets
EU/1/15/1073/003 100 x 1 film-coated tablet
EU/1/15/1073/023 14 x 1 film-coated tablet

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Briviact 10 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

<2D barcode carrying the unique identifier included.>

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC:
SN:
NN:
1. **NAME OF THE MEDICINAL PRODUCT**

Briviact 10 mg film-coated tablets
brivaracetam

2. **STATEMENT OF ACTIVE SUBSTANCE(S)**

Each film-coated tablet contains 10 mg brivaracetam.

3. **LIST OF EXCIPIENTS**

Contains croscarmellose sodium, lactose monohydrate and lactose anhydrous.
See leaflet for further information. *(Omitted from cartons of 14 film-coated tablets)*

4. **PHARMACEUTICAL FORM AND CONTENTS**

Multipack: 168 (3 packs of 56) film-coated tablets

5. **METHOD AND ROUTE(S) OF ADMINISTRATION**

Read the package leaflet before use.
Oral use

6. **SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

7. **OTHER SPECIAL WARNING(S), IF NECESSARY**

8. **EXPIRY DATE**

**EXP**

9. **SPECIAL STORAGE CONDITIONS**
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

UCB Pharma S.A.
Allée de la Recherche 60
B-1070 Brussels
Belgium

12. MARKETING AUTHORIZATION NUMBER(S)

EU/1/15/1073/004 168 (3 packs of 56) film-coated tablets

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Briviact 10 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

<2D barcode carrying the unique identifier included.>

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC:
SN:
NN:
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
INTERMEDIATE CARTON WITHIN MULTIPACK (3 PACKS OF 56 FILM-COATED TABLETS) (WITHOUT BLUE BOX)

1. NAME OF THE MEDICINAL PRODUCT
Briviact 10 mg film-coated tablets
brivaracetam

2. STATEMENT OF ACTIVE SUBSTANCE(S)
Each film-coated tablet contains 10 mg brivaracetam.

3. LIST OF EXCIPIENTS
Contains croscarmellose sodium, lactose monohydrate and lactose anhydrous.
See leaflet for further information. *(Omitted from cartons of 14 film-coated tablets)*

4. PHARMACEUTICAL FORM AND CONTENTS
56 film-coated tablets. Component of a multipack, can’t be sold separately.

5. METHOD AND ROUTE(S) OF ADMINISTRATION
Read the package leaflet before use.
Oral use

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN
Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE
EXP

9. SPECIAL STORAGE CONDITIONS
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

UCB Pharma S.A.
Allée de la Recherche 60
B-1070 Brussels
Belgium

12. MARKETING AUTHORISATION NUMBER(S)

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Briviact 10 mg
### MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

#### BLISTER

1. **NAME OF THE MEDICINAL PRODUCT**
   
   Briviact 10 mg tablets
   brivaracetam

2. **NAME OF THE MARKETING AUTHORISATION HOLDER**
   
   UCB Pharma S.A. (logo)

3. **EXPIRY DATE**
   
   EXP

4. **BATCH NUMBER**
   
   Lot

5. **OTHER**
   
   Calendar days: Mon., Tue., Wed., Thu., Fri., Sat., Sun.
   
   *(not for packsizes 14 x 1 and 100 x 1 film-coated tablet)*
### PARTICULARS TO APPEAR ON THE OUTER PACKAGING

#### OUTER CARTON

1. **NAME OF THE MEDICINAL PRODUCT**

   Briviact 25 mg film-coated tablets
   brivaracetam

2. **STATEMENT OF ACTIVE SUBSTANCE(S)**

   Each film-coated tablet contains 25 mg brivaracetam.

3. **LIST OF EXCIPIENTS**

   Contains croscarmellose sodium, lactose monohydrate and lactose anhydrous.
   See leaflet for further information. *(Omitted from cartons of 14 film-coated tablets)*

4. **PHARMACEUTICAL FORM AND CONTENTS**

   - 14 film-coated tablets
   - 56 film-coated tablets
   - 100 x 1 film-coated tablet
   - 14 x 1 film-coated tablet

5. **METHOD AND ROUTE(S) OF ADMINISTRATION**

   Read the package leaflet before use.
   Oral use

6. **SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

   Keep out of the sight and reach of children.

7. **OTHER SPECIAL WARNING(S), IF NECESSARY**

8. **EXPIRY DATE**

   EXP

9. **SPECIAL STORAGE CONDITIONS**
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS
OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF
APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

UCB Pharma S.A.
Allée de la Recherche 60
B-1070 Brussels
Belgium

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/15/1073/005 14 film-coated tablets
EU/1/15/1073/006 56 film-coated tablets
EU/1/15/1073/007 100 x 1 film-coated tablet
EU/1/15/1073/024 14 x 1 film-coated tablet

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Briviact 25 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

<2D barcode carrying the unique identifier included.>

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC:
SN:
NN:
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON OF MULTIPACK (WITH BLUE BOX)

1. NAME OF THE MEDICINAL PRODUCT

Briviact 25 mg film-coated tablets
brivaracetam

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each film-coated tablet contains 25 mg brivaracetam.

3. LIST OF EXCIPIENTS

Contains croscarmellose sodium, lactose monohydrate and lactose anhydrous.
See leaflet for further information. *(Omitted from cartons of 14 film-coated tablets)*

4. PHARMACEUTICAL FORM AND CONTENTS

Multipack: 168 (3 packs of 56) film-coated tablets

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
Oral use

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

UCB Pharma S.A.
Allée de la Recherche 60
B-1070 Brussels
Belgium

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/15/1073/008 168 (3 packs of 56) film-coated tablets

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Briviact 25 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

<2D barcode carrying the unique identifier included.>

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC:
SN:
NN:
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
INTERMEDIATE CARTON WITHIN MULTIPACK (3 PACKS OF 56 FILM-COATED TABLETS) (WITHOUT BLUE BOX)

1. NAME OF THE MEDICINAL PRODUCT
Briviact 25 mg film-coated tablets
brivaracetam

2. STATEMENT OF ACTIVE SUBSTANCE(S)
Each film-coated tablet contains 25 mg brivaracetam.

3. LIST OF EXCIPIENTS
Contains croscarmellose sodium, lactose monohydrate and lactose anhydrous.
See leaflet for further information. (Omitted from cartons of 14 film-coated tablets)

4. PHARMACEUTICAL FORM AND CONTENTS
56 film-coated tablets. Component of a multipack, can’t be sold separately.

5. METHOD AND ROUTE(S) OF ADMINISTRATION
Read the package leaflet before use.
Oral use

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN
Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE
EXP

9. SPECIAL STORAGE CONDITIONS
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

UCB Pharma S.A.
Allée de la Recherche 60
B-1070 Brussels
Belgium

12. MARKETING AUTHORISATION NUMBER(S)

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Briviact 25 mg
### MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

#### BLISTER

<table>
<thead>
<tr>
<th>1. NAME OF THE MEDICINAL PRODUCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Briviact 25 mg tablets</td>
</tr>
<tr>
<td>brivaracetam</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2. NAME OF THE MARKETING AUTHORISATION HOLDER</th>
</tr>
</thead>
<tbody>
<tr>
<td>UCB Pharma S.A. (logo)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3. EXPIRY DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXP</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4. BATCH NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lot</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5. OTHER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calendar days: Mon., Tue., Wed., Thu., Fri., Sat., Sun.</td>
</tr>
</tbody>
</table>

*(not for packsizes 14 x 1 and 100 x 1 film-coated tablet)*
1. NAME OF THE MEDICINAL PRODUCT

Briviact 50 mg film-coated tablets
brivaracetam

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each film-coated tablet contains 50 mg brivaracetam.

3. LIST OF EXCIPIENTS

Contains croscarmellose sodium, lactose monohydrate and lactose anhydrous.
See leaflet for further information. *(Omitted from cartons of 14 film-coated tablets)*

4. PHARMACEUTICAL FORM AND CONTENTS

14 film-coated tablets
56 film-coated tablets
100 x 1 film-coated tablet
14 x 1 film-coated tablet

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
Oral use

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

UCB Pharma S.A.
Allée de la Recherche 60
B-1070 Brussels
Belgium

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/15/1073/009 14 film-coated tablets
EU/1/15/1073/010 56 film-coated tablets
EU/1/15/1073/011 100 x 1 film-coated tablet
EU/1/15/1073/025 14 x 1 film-coated tablet

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Briviact 50 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

<2D barcode carrying the unique identifier included.>

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC:
SN:
NN:
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON of MULTIPACK (WITH BLUE BOX)

1. NAME OF THE MEDICINAL PRODUCT

Briviact 50 mg film-coated tablets
brivaracetam

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each film-coated tablet contains 50 mg brivaracetam.

3. LIST OF EXCIPIENTS

Contains croscarmellose sodium, lactose monohydrate and lactose anhydrous.
See leaflet for further information. *(Omitted from cartons of 14 film-coated tablets)*

4. PHARMACEUTICAL FORM AND CONTENTS

Multipack: 168 (3 packs of 56) film-coated tablets

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
Oral use

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY


8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS
<table>
<thead>
<tr>
<th>Section</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS</td>
<td>OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</td>
</tr>
<tr>
<td>11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</td>
<td>UCB Pharma S.A.</td>
</tr>
<tr>
<td></td>
<td>Allée de la Recherche 60</td>
</tr>
<tr>
<td></td>
<td>B-1070 Brussels</td>
</tr>
<tr>
<td></td>
<td>Belgium</td>
</tr>
<tr>
<td>12. MARKETING AUTHORISATION NUMBER(S)</td>
<td>EU/1/15/1073/012 168 (3 packs of 56) film-coated tablets</td>
</tr>
<tr>
<td>13. BATCH NUMBER</td>
<td>Lot</td>
</tr>
<tr>
<td>14. GENERAL CLASSIFICATION FOR SUPPLY</td>
<td></td>
</tr>
<tr>
<td>15. INSTRUCTIONS ON USE</td>
<td>Briviact 50 mg</td>
</tr>
<tr>
<td>16. INFORMATION IN BRAILLE</td>
<td></td>
</tr>
<tr>
<td>17. UNIQUE IDENTIFIER – 2D BARCODE</td>
<td>&lt;2D barcode carrying the unique identifier included.&gt;</td>
</tr>
<tr>
<td>18. UNIQUE IDENTIFIER - HUMAN READABLE DATA</td>
<td>PC:</td>
</tr>
<tr>
<td></td>
<td>SN:</td>
</tr>
<tr>
<td></td>
<td>NN:</td>
</tr>
</tbody>
</table>
### PARTICULARS TO APPEAR ON THE OUTER PACKAGING

**INTERMEDIATE CARTON WITHIN MULTIPACK (3 PACKS OF 56 FILM-COATED TABLETS)**

(WITHOUT BLUE BOX)

<table>
<thead>
<tr>
<th>Section</th>
<th>Information</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. NAME OF THE MEDICINAL PRODUCT</strong></td>
<td>Briviact 50 mg film-coated tablets \ brivaracetam</td>
</tr>
<tr>
<td><strong>2. STATEMENT OF ACTIVE SUBSTANCE(S)</strong></td>
<td>Each film-coated tablet contains 50 mg brivaracetam.</td>
</tr>
<tr>
<td><strong>3. LIST OF EXCIPIENTS</strong></td>
<td>Contains croscarmellose sodium, lactose monohydrate and lactose anhydrous. \ See leaflet for further information. <em>(Omitted from cartons of 14 film-coated tablets)</em></td>
</tr>
<tr>
<td><strong>4. PHARMACEUTICAL FORM AND CONTENTS</strong></td>
<td>56 film-coated tablets. Component of a multipack, can’t be sold separately.</td>
</tr>
<tr>
<td><strong>5. METHOD AND ROUTE(S) OF ADMINISTRATION</strong></td>
<td>Read the package leaflet before use. \ Oral use</td>
</tr>
<tr>
<td><strong>6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</strong></td>
<td>Keep out of the sight and reach of children.</td>
</tr>
<tr>
<td><strong>7. OTHER SPECIAL WARNING(S), IF NECESSARY</strong></td>
<td></td>
</tr>
<tr>
<td><strong>8. EXPIRY DATE</strong></td>
<td>EXP</td>
</tr>
<tr>
<td><strong>9. SPECIAL STORAGE CONDITIONS</strong></td>
<td></td>
</tr>
</tbody>
</table>
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

UCB Pharma S.A.
Allée de la Recherche 60
B-1070 Brussels
Belgium

12. MARKETING AUTHORISATION NUMBER(S)

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Briviact 50 mg
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

1. NAME OF THE MEDICINAL PRODUCT

Briviact 50 mg tablets
brivaracetam

2. NAME OF THE MARKETING AUTHORISATION HOLDER

UCB Pharma S.A. (logo)

3. EXPIRY DATE

EXP

4. BATCH NUMBER

Lot

5. OTHER

Calendar days: Mon., Tue., Wed., Thu., Fri., Sat., Sun.

(not for packsizes 14 x 1 and 100 x 1 film-coated tablet)
<table>
<thead>
<tr>
<th>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</th>
</tr>
</thead>
</table>

OUTER CARTON

1. **NAME OF THE MEDICINAL PRODUCT**

   Briviact 75 mg film-coated tablets
   brivaracetam

2. **STATEMENT OF ACTIVE SUBSTANCE(S)**

   Each film-coated tablet contains 75 mg brivaracetam.

3. **LIST OF EXCIPIENTS**

   Contains croscarmellose sodium, lactose monohydrate and lactose anhydrous.
   See leaflet for further information. *(Omitted from cartons of 14 film-coated tablets)*

4. **PHARMACEUTICAL FORM AND CONTENTS**

   14 film-coated tablets
   56 film-coated tablets
   100 x 1 film-coated tablet
   14 x 1 film-coated tablet

5. **METHOD AND ROUTE(S) OF ADMINISTRATION**

   Read the package leaflet before use.
   Oral use

6. **SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

   Keep out of the sight and reach of children.

7. **OTHER SPECIAL WARNING(S), IF NECESSARY**

8. ** EXPIRY DATE**

   EXP

9. **SPECIAL STORAGE CONDITIONS**
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

UCB Pharma S.A.
Allée de la Recherche 60
B-1070 Brussels
Belgium

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/15/1073/013 14 film-coated tablets
EU/1/15/1073/014 56 film-coated tablets
EU/1/15/1073/015 100 x 1 film-coated tablet
EU/1/15/1073/026 14 x 1 film-coated tablet

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Briviact 75 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

<2D barcode carrying the unique identifier included.>

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC:
SN:
NN:
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
OUTER CARTON of MULTIPACK (WITH BLUE BOX)

1. NAME OF THE MEDICINAL PRODUCT

Briviact 75 mg film-coated tablets
brivaracetam

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each film-coated tablet contains 75 mg brivaracetam.

3. LIST OF EXCIPIENTS

Contains croscarmellose sodium, lactose monohydrate and lactose anhydrous.
See leaflet for further information. (Omitted from cartons of 14 film-coated tablets)

4. PHARMACEUTICAL FORM AND CONTENTS

Multipack: 168 (3 packs of 56) film-coated tablets

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
Oral use

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT
   OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY


8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

UCB Pharma S.A.
Allée de la Recherche 60
B-1070 Brussels
Belgium

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/15/1073/016 168 (3 packs of 56) film-coated tablets

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Briviact 75 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

<2D barcode carrying the unique identifier included.>

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC:
SN:
NN:
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
INTERMEDIATE CARTON WITHIN MULTIPACK (3 PACKS OF 56 FILM-COATED TABLETS) (WITHOUT BLUEBOX)

1. NAME OF THE MEDICINAL PRODUCT

Briviact 75 mg film-coated tablets
brivaracetam

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each film-coated tablet contains 75 mg brivaracetam.

3. LIST OF EXCIPIENTS

Contains croscarmellose sodium, lactose monohydrate and lactose anhydrous.
See leaflet for further information. (Omitted from cartons of 14 film-coated tablets)

4. PHARMACEUTICAL FORM AND CONTENTS

56 film-coated tablets. Component of a multipack, can’t be sold separately.

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
Oral use

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS
<table>
<thead>
<tr>
<th>Section</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.</td>
<td>SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</td>
</tr>
<tr>
<td>11.</td>
<td>NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</td>
</tr>
</tbody>
</table>
| | UCB Pharma S.A.  
| | Allée de la Recherche 60  
| | B-1070 Brussels  
| | Belgium |
| 12. | MARKETING AUTHORISATION NUMBER(S) |
| 13. | BATCH NUMBER |
| | Lot |
| 14. | GENERAL CLASSIFICATION FOR SUPPLY |
| 15. | INSTRUCTIONS ON USE |
| 16. | INFORMATION IN BRAILLE |
| | Briviact 75 mg |
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

BLISTER

1. NAME OF THE MEDICINAL PRODUCT

Briviact 75 mg tablets
brivaracetam

2. NAME OF THE MARKETING AUTHORISATION HOLDER

UCB Pharma S.A. (logo)

3. EXPIRY DATE

EXP

4. BATCH NUMBER

Lot

5. OTHER

Calendar days: Mon., Tue., Wed., Thu., Fri., Sat., Sun.

(not for pack sizes 14 x 1 and 100 x 1 film-coated tablet)
<table>
<thead>
<tr>
<th>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</th>
</tr>
</thead>
<tbody>
<tr>
<td>OUTER CARTON</td>
</tr>
</tbody>
</table>

1. **NAME OF THE MEDICINAL PRODUCT**

Briviact 100 mg film-coated tablets
brivaracetam

2. **STATEMENT OF ACTIVE SUBSTANCE(S)**

Each film-coated tablet contains 100 mg brivaracetam.

3. **LIST OF EXCIPIENTS**

Contains croscarmellose sodium, lactose monohydrate and lactose anhydrous.
See leaflet for further information. *(Omitted from cartons of 14 film-coated tablets)*

4. **PHARMACEUTICAL FORM AND CONTENTS**

<table>
<thead>
<tr>
<th>14 film-coated tablets</th>
</tr>
</thead>
<tbody>
<tr>
<td>56 film-coated tablets</td>
</tr>
<tr>
<td>100 x 1 film-coated tablet</td>
</tr>
<tr>
<td>14 x 1 film-coated tablet</td>
</tr>
</tbody>
</table>

5. **METHOD AND ROUTE(S) OF ADMINISTRATION**

Read the package leaflet before use.
Oral use

6. **SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

7. **OTHER SPECIAL WARNING(S), IF NECESSARY**

8. **EXPIRY DATE**

EXP

9. **SPECIAL STORAGE CONDITIONS**
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

UCB Pharma S.A.
Allée de la Recherche 60
B-1070 Brussels
Belgium

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/15/1073/017 14 film-coated tablets
EU/1/15/1073/018 56 film-coated tablets
EU/1/15/1073/019 100 x 1 film-coated tablet
EU/1/15/1073/027 14 x 1 film-coated tablet

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Briviact 100 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

<2D barcode carrying the unique identifier included.>

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC:
SN:
NN:
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON OF MULTIPACK (WITH BLUE BOX)

1. NAME OF THE MEDICINAL PRODUCT

Briviact 100 mg film-coated tablets
brivaracetam

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each film-coated tablet contains 100 mg brivaracetam.

3. LIST OF EXCIPIENTS

Contains croscarmellose sodium, lactose monohydrate and lactose anhydrous.
See leaflet for further information. *(Omitted from cartons of 14 film-coated tablets)*

4. PHARMACEUTICAL FORM AND CONTENTS

Multipack: 168 (3 packs of 56) film-coated tablets

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
Oral use

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

UCB Pharma S.A.
Allée de la Recherche 60
B-1070 Brussels
Belgium

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/15/1073/020 168 (3 packs of 56) film-coated tablets

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Briviact 100 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

<2D barcode carrying the unique identifier included.>

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC:
SN:
NN:
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
INTERMEDIATE CARTON WITHIN MULTIPACK (3 PACKS OF 56 FILM-COATED TABLETS)
(WITHOUT BLUE BOX)

1. NAME OF THE MEDICINAL PRODUCT

Briviact 100 mg film-coated tablets
brivaracetam

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each film-coated tablet contains 100 mg brivaracetam.

3. LIST OF EXCIPIENTS

Contains croscarmellose sodium, lactose monohydrate and lactose anhydrous.
See leaflet for further information. (Omitted from cartons of 14 film-coated tablets)

4. PHARMACEUTICAL FORM AND CONTENTS

56 film-coated tablets. Component of a multipack, can be sold separately.

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
Oral use

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY


8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

UCB Pharma S.A.
Allée de la Recherche 60
B-1070 Brussels
Belgium

12. MARKETING AUTHORISATION NUMBER(S)

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Briviact 100 mg
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

BLISTER

1. NAME OF THE MEDICINAL PRODUCT

Briviact 100 mg tablets
brivaracetam

2. NAME OF THE MARKETING AUTHORISATION HOLDER

UCB Pharma S.A. (logo)

3. EXPIRY DATE

EXP

4. BATCH NUMBER

Lot

5. OTHER

Calendar days: Mon., Tue., Wed., Thu., Fri., Sat., Sun.

*(not for packsizes 14 x 1 and 100 x 1 film-coated tablet)*
PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND IMMEDIATE PACKAGING

OUTER CARTON / BOTTLE

1. NAME OF THE MEDICINAL PRODUCT

Briviact 10 mg/ml oral solution
brivaracetam

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each ml of oral solution contains 10 mg brivaracetam.

3. LIST OF EXCIPIENTS

Contains sodium citrate, carmellose sodium, methyl parahydroxybenzoate (E218), sorbitol liquid and glycerol (E422).
See leaflet for further information. (Only for outer carton)

4. PHARMACEUTICAL FORM AND CONTENTS

300 ml oral solution
Use the 10 ml oral syringe included in the package.

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
Oral use

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP
After first opening of the bottle, use within 5 months.
Opening date (Only for outer carton)

9. SPECIAL STORAGE CONDITIONS
10. **SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

11. **NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

UCB Pharma S.A.
Allée de la Recherche 60 *(address only for outer carton)*
B-1070 Brussels
Belgium

12. **MARKETING AUTHORISATION NUMBER(S)**

EU/1/15/1073/021 oral solution with 10 ml oral syringe

13. **BATCH NUMBER**

Lot

14. **GENERAL CLASSIFICATION FOR SUPPLY**

15. **INSTRUCTIONS ON USE**

16. **INFORMATION IN BRAILLE**

Briviact 10 mg/ml *(Only for outer carton)*

17. **UNIQUE IDENTIFIER – 2D BARCODE**

<2D barcode carrying the unique identifier included>

18. **UNIQUE IDENTIFIER - HUMAN READABLE DATA**

PC:
SN:
NN:
### PARTICULARS TO APPEAR ON THE OUTER PACKAGING

#### OUTER CARTON

**1. NAME OF THE MEDICINAL PRODUCT**

Briviact 10 mg/ml solution for injection/infusion  
brivaracetam

**2. STATEMENT OF ACTIVE SUBSTANCE(S)**

Each ml of solution for injection/infusion contains 10 mg brivaracetam.  
One vial of 5 ml contains 50 mg brivaracetam.

**3. LIST OF EXCIPIENTS**

Contains sodium acetate (trihydrate), sodium chloride.  
See leaflet for further information.

**4. PHARMACEUTICAL FORM AND CONTENTS**

50 mg/5 ml  
10 vials solution for injection/infusion

**5. METHOD AND ROUTE(S) OF ADMINISTRATION**

Read the package leaflet before use.  
Intravenous use

**6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

**7. OTHER SPECIAL WARNING(S), IF NECESSARY**

**8. EXPIRY DATE**

EXP

**9. SPECIAL STORAGE CONDITIONS**
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

UCB Pharma S.A.
Allée de la Recherche 60
B-1070 Brussels
Belgium

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/15/1073/022

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

<Justification for not including Braille accepted>

17. UNIQUE IDENTIFIER – 2D BARCODE

<2D barcode carrying the unique identifier included>

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC:
SN:
NN:
# MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

## VIAL

### 1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION

Briviact 10 mg/ml injection/infusion  
brivaracetam  
IV

### 2. METHOD OF ADMINISTRATION

### 3. EXPIRY DATE

EXP

### 4. BATCH NUMBER

Lot

### 5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

50 mg/5 ml

### 6. OTHER
B. PACKAGE LEAFLET
This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet
1. What Briviact is and what it is used for
2. What you need to know before you take Briviact
3. How to take Briviact
4. Possible side effects
5. How to store Briviact
6. Contents of the pack and other information

1. What Briviact is and what it is used for

What Briviact is
Briviact contains the active substance brivaracetam. It belongs to a group of medicines called ‘anti-epileptics’. These medicines are used to treat epilepsy.

What Briviact is used for
Briviact is used in adults and adolescents from 16 years of age to treat a type of epilepsy characterized by the occurrence of partial seizures with or without secondary generalisation. Partial seizures are fits that start by only affecting one side of the brain. These partial seizures can spread and extend to larger areas on both sides of the brain – this is called a ‘secondary generalisation’. You have been given this medicine to lower the number of fits (seizures) you have. Briviact is used together with other medicines for epilepsy.

2. What you need to know before you take Briviact

Do not take Briviact if:
- you are allergic to brivaracetam, other pyrrolidone derivatives or any of the other ingredients of this medicine (listed in section 6). If you are not sure, talk to your doctor or pharmacist before taking Briviact.

Warnings and precautions
Talk to your doctor or pharmacist before taking Briviact if:
- You have thoughts of harming or killing yourself. A small number of people being treated with anti-epileptic medicines such as Briviact have had thoughts of harming or killing themselves. If
you have any of these thoughts at any time, contact your doctor immediately.
- You have liver problems your doctor may need to adjust your dose.

**Children and young people**
Briviact is not recommended for use in children and young people under 16 years of age.

**Other medicines and Briviact**
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
In particular, your doctor may need to adjust your Briviact dose if you take the following medicines:
- Rifampicin, a medicine used to treat bacterial infections.
- St John’s wort, (also known as Hypericum perforatum) a herbal medicine used to treat depression and anxiety and other conditions.

**Briviact with alcohol**
- Combining this medicine with alcohol is not recommended.
- If you drink alcohol while taking Briviact the negative effects of alcohol may be increased.

**Pregnancy and breast-feeding**
It is not recommended to take Briviact if you are pregnant or breast-feeding, as the effects of Briviact on pregnancy and the unborn baby or the new-born child are not known. Seek advice immediately from your doctor if you are pregnant or are planning to become pregnant.

Do not stop treatment without talking to your doctor first as this could increase your seizures and a worsening of your disease can harm your baby.

**Driving and using machines**
- You may feel sleepy, dizzy or tired while taking Briviact.
- These effects are more likely at the start of the treatment or after a dose increase.
- Do not drive, cycle or use any tools or machines until you know how the medicine affects you.

**Briviact contains lactose**
Briviact film-coated tablets contain lactose (a type of sugar). If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.

3. **How to take Briviact**

Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

You will take Briviact together with other medicines for epilepsy.

**How much to take**
- The recommended dose is between 50 mg and 200 mg each day, your doctor may decide to adjust your optimal dose within the dose range.
- Take the medicine in two equally divided doses - once in the morning and once in the evening at about the same time each day.

**People with liver problems**
If you have problem with your liver, the maximum dose you will take is 150 mg each day.

**How to take Briviact tablets**
- Swallow the tablets whole with a glass of liquid.
- The medicine may be taken with or without food.
How long to take Briviact for
Briviact is a long term treatment – keep taking Briviact until your doctor tells you to stop.

If you take more Briviact than you should
If you have taken more Briviact than you should, talk to your doctor. You may feel dizzy and sleepy.

If you forget to take Briviact
- If you miss a dose take it as soon as you remember.
- Then take your next dose at the time you would normally take it.
- Do not take a double dose to make up for a forgotten dose.
- If you are not sure what to do, ask your doctor or pharmacist

If you stop taking Briviact
- Do not stop taking this medicine unless your doctor tells you to. This is because stopping treatment could increase the number of fits you have.
- If your doctor asks you to stop taking this medicine they will lower your dose gradually. This helps to stop your fits coming back or getting worse

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Very common: may affect more than 1 in 10 people
- feeling sleepy or dizzy.

Common: may affect up to 1 in 10 people
- flu
- feeling very tired (fatigue)
- convulsion, a feeling of ‘spinning’ (vertigo)
- feeling and being sick, constipation
- depression, anxiety, unable to sleep (insomnia), irritability
- infections of the nose and throat (such as the ‘common cold’), cough
- decreased appetite

Uncommon: may affect up to 1 in 100 people
- allergic reactions
- psychotic disorder, being aggressive, thoughts or attempts of harming or killing yourself, nervous excitement (agitation)
- a decrease in white blood cells (called ‘neutropenia’) - shown in blood tests

Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Briviact
- Keep this medicine out of the sight and reach of children.
- Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.
- This medicinal product does not require any special storage conditions.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Briviact contains
The active substance is brivaracetam.
Each film-coated tablet contains 10 mg, 25 mg, 50 mg, 75 mg, or 100 mg brivaracetam.

The other ingredients are:
Core
Croscarmellose sodium, lactose monohydrate, betadex, lactose anhydrous, magnesium stearate

Coating
- 10 mg film-coated tablets: polyvinyl alcohol, titanium dioxide (E171), macrogol 3350, talc.
- 25 mg film-coated tablets: polyvinyl alcohol, titanium dioxide (E171), macrogol 3350, talc, iron oxide yellow (E172), iron oxide black (E172).
- 50 mg film-coated tablets: polyvinyl alcohol, titanium dioxide (E171), macrogol 3350, talc, iron oxide yellow (E172), iron oxide red (E172).
- 75 mg film-coated tablets: polyvinyl alcohol, titanium dioxide (E171), macrogol 3350, talc, iron oxide yellow (E172), iron oxide red (E172), iron oxide black (E172).
- 100 mg film-coated tablets: polyvinyl alcohol, titanium dioxide (E171), macrogol 3350, talc, iron oxide yellow (E172), iron oxide black (E172).

What Briviact looks like and contents of the pack
Briviact 10 mg are white to off-white, round, film-coated tablets of 6.5 mm in diameter and debossed with ‘u10’ on one side.
Briviact 25 mg are grey, oval, film-coated tablets of 8.9 mm x 5.0 mm and debossed with ‘u25’ on one side.
Briviact 50 mg are yellow, oval, film-coated tablets of 11.7 mm x 6.6 mm and debossed with ‘u50’ on one side.
Briviact 75 mg are purple, oval, film-coated tablets of 13.0 mm x 7.3 mm and debossed with ‘u75’ on one side.
Briviact 100 mg are green-grey, oval, film-coated tablets of 14.5 mm x 8.1 mm and debossed with ‘u100’ on one side.

Briviact tablets are packaged in blister packs supplied in cardboard boxes containing either 14, 56 or 14 x 1 or 100 x 1 film-coated tablets or in multipacks containing 168 (3 packs of 56) film-coated tablets.
All packs are available in PVC/PCTFE - Aluminium blisters.

Not all pack sizes may be marketed.

Marketing Authorisation Holder
UCB Pharma S.A., Allée de la Recherche 60, B-1070 Bruxelles, Belgium.

Manufacturer
UCB Pharma S.A., Chemin du Foriest, B-1420 Braine-l’Alleud, Belgium

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

Belgïe/Belgique/Belgien
UCB Pharma SA/NV
Tél/Tel: + 32 / (0)2 559 92 00

Lietuva
UCB Pharma Oy Finland
Tel: + 358 9 2514 4221 (Suomija)
<table>
<thead>
<tr>
<th>Country</th>
<th>Company Name</th>
<th>Phone Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>България</td>
<td>България ЕООД</td>
<td>Тел.: + 359 (0) 2 962 30 49</td>
</tr>
<tr>
<td>Česká republika</td>
<td>UCB s.r.o.</td>
<td>Tel: + 420 221 773 411</td>
</tr>
<tr>
<td>Danmark</td>
<td>UCB Nordic A/S</td>
<td>Tlf: + 45 / 32 46 24 00</td>
</tr>
<tr>
<td>Deutschland</td>
<td>UCB Pharma GmbH</td>
<td>Tel: + 49 (0) 2173 48 4848</td>
</tr>
<tr>
<td>Eesti</td>
<td>UCB Pharma Oy Finland</td>
<td>Tel: + 358 9 2514 4221 (Soome)</td>
</tr>
<tr>
<td>Elláda</td>
<td>UCB A.E.</td>
<td>Tel.: + 30 / 2109974000</td>
</tr>
<tr>
<td>España</td>
<td>UCB Pharma, S.A.</td>
<td>Tel: + 34 / 91 570 34 44</td>
</tr>
<tr>
<td>France</td>
<td>UCB Pharma S.A.</td>
<td>Tel: + 33 / (0)1 47 29 44 35</td>
</tr>
<tr>
<td>Hrvatska</td>
<td>Medis Adria d.o.o.</td>
<td>Tel: +385 (0) 1 230 34 46</td>
</tr>
<tr>
<td>Ireland</td>
<td>UCB (Pharma) Ireland Ltd.</td>
<td>Tel: + 353 / (0)1-46 37 395</td>
</tr>
<tr>
<td>Ísland</td>
<td>Vistor hf.</td>
<td>Simi: + 354 535 7000</td>
</tr>
<tr>
<td>Italia</td>
<td>UCB Pharma S.p.A.</td>
<td>Tel: + 39 / 02 300 791</td>
</tr>
<tr>
<td>Kύπρος</td>
<td>Lifepharma (Z.A.M.) Ltd</td>
<td>Τηλ.: + 357 22 34 74 40</td>
</tr>
<tr>
<td>Latvija</td>
<td>UCB Pharma Oy Finland</td>
<td>Tel: + 358 9 2514 4221 (Somija)</td>
</tr>
<tr>
<td>Luxembourg/Luxemburg</td>
<td>UCB Pharma SA/NV</td>
<td>Tél/Tel: + 32 / (0)2 559 92 00</td>
</tr>
<tr>
<td>Magyarország</td>
<td>UCB Magyarország Kft.</td>
<td>Tel.: + 36-(1) 391 0060</td>
</tr>
<tr>
<td>Malta</td>
<td>Pharmasud Ltd.</td>
<td>Tel: + 356 / 21 37 64 36</td>
</tr>
<tr>
<td>Nederland</td>
<td>UCB Pharma B.V.</td>
<td>Tel.: + 31 / (0)76-573 11 40</td>
</tr>
<tr>
<td>Norge</td>
<td>UCB Nordic A/S</td>
<td>Tlf: + 45 / 32 46 24 00</td>
</tr>
<tr>
<td>Österreich</td>
<td>UCB Pharma GmbH</td>
<td>Tel: + 43-(0)1 291 80 00</td>
</tr>
<tr>
<td>Polska</td>
<td>UCB Pharma Sp. z o.o.</td>
<td>Tel: + 48 22 696 99 20</td>
</tr>
<tr>
<td>Portugal</td>
<td>UCB Pharma (Produtos Farmacêuticos), Lda</td>
<td>Tel: + 351 / 21 302 5300</td>
</tr>
<tr>
<td>România</td>
<td>UCB Pharma Romania S.R.L.</td>
<td>Tel: + 40 21 300 29 04</td>
</tr>
<tr>
<td>Slovenija</td>
<td>Medis, d.o.o.</td>
<td>Tel: + 386 1 589 69 00</td>
</tr>
<tr>
<td>Slovenská republika</td>
<td>UCB s.r.o., organizačná zložka</td>
<td>Tel: + 421 (0) 2 5920 2020</td>
</tr>
<tr>
<td>Sverige</td>
<td>UCB Nordic A/S</td>
<td>Tel: + 46 / (0) 40 29 49 00</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>UCB Pharma Ltd.</td>
<td>Tel : + 44 / (0)1753 534 655</td>
</tr>
</tbody>
</table>
This leaflet was last revised in {month YYYY}.

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu.
This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet
1. What Briviact is and what it is used for
2. What you need to know before you take Briviact
3. How to take Briviact
4. Possible side effects
5. How to store Briviact
6. Contents of the pack and other information

1. What Briviact is and what it is used for

What Briviact is
Briviact contains the active substance brivaracetam. It belongs to a group of medicines called ‘anti-epileptics’. These medicines are used to treat epilepsy.

What Briviact is used for
Briviact is used in adults and adolescents from 16 years of age to treat a type of epilepsy characterized by the occurrence of partial seizures with or without secondary generalization’. Partial seizures are fits that start by only affecting one side of the brain. These partial seizures can spread and extend to larger areas on both sides of the brain – this is called a ‘secondary generalisation’. You have been given this medicine to lower the number of fits (seizures) you have. Briviact is used together with other medicines for epilepsy.

2. What you need to know before you take Briviact

Do not take Briviact if:
- you are allergic to brivaracetam, other pyrrolidone derivatives or any of the other ingredients of this medicine (listed in section 6). If you are not sure, talk to your doctor or pharmacist before taking Briviact.

Warnings and precautions
Talk to your doctor or pharmacist before taking Briviact if:
- You have thoughts of harming or killing yourself. A small number of people being treated with anti-epileptic medicines such as Briviact have had thoughts of harming or killing themselves. If you have any of these thoughts at any time, contact your doctor immediately.
- You have liver problems your doctor may need to adjust your dose.

Children and young people
Briviact is not recommended for use in children and young people under 16 years of age.

Other medicines and Briviact
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
In particular, your doctor may need to adjust your Briviact dose if you take the following medicines:
- Rifampicin, a medicine used to treat bacterial infections.
- St John’s wort, (also known as Hypericum perforatum) a herbal medicine used to treat depression and anxiety and other conditions.

Briviact with alcohol
- Combining this medicine with alcohol is not recommended.
- If you drink alcohol while taking Briviact the negative effects of alcohol may be increased.

Pregnancy and breast-feeding
It is not recommended to take Briviact if you are pregnant or breast-feeding, as the effects of Briviact on pregnancy and the unborn baby or the new-born child are not known. Seek advice immediately from your doctor if you are pregnant or are planning to become pregnant.

Do not stop treatment without talking to your doctor first as this could increase your seizures and a worsening of your disease can harm your baby.

Driving and using machines
- You may feel sleepy, dizzy or tired while taking Briviact.
- These effects are more likely at the start of the treatment or after a dose increase.
- Do not drive, cycle or use any tools or machines until you know how the medicine affects you.

Briviact oral solution contains methyl parahydroxybenzoate, sodium and sorbitol
Briviact oral solution contains:
- methyl parahydroxybenzoate (E218) - this may cause allergic reactions (possibly delayed).
- 1.16 milligrams sodium per millilitre. If you are on a low sodium diet, you need to take this into account.
- sorbitol (a type of sugar). If you have been told by your doctor that you cannot tolerate or digest some sugars, contact your doctor before taking this medicine.

3. How to take Briviact

Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

You will take Briviact together with other medicines for epilepsy.

How much to take
- The recommended dose is between 50 mg and 200 mg each day, your doctor may decide to adjust your optimal dose within the dose range.
- Take the medicine in two equally divided doses - once in the morning and once in the evening at about the same time each day.

People with liver problems
If you have problem with your liver, the maximum dose you will take is 150 mg each day.

How to take Briviact oral solution
- You can take Briviact oral solution on its own, or dilute it in water or juice shortly before swallowing.
- The medicine may be taken with or without food.
Instructions for use for patients/ carers:

- Open the bottle: press the cap and turn it anticlockwise (figure 1)

Follow these steps the first time you take Briviact:
- Take off the adaptor from the oral syringe (figure 2).
- Put the adaptor into the top of the bottle (figure 3). Make sure it is fixed well in place. You do not need to remove the adaptor after use.

Follow these steps each time you take Briviact:
- Take the oral syringe and put it in the adaptor opening (figure 4).
- Turn the bottle upside down (figure 5).

- Hold the bottle upside down in one hand and use the other hand to fill the oral syringe.
- Fill the oral syringe with a small amount of solution by pulling the plunger down (figure 5A),
- Then push the plunger to remove any possible air bubble (figure 5B).
- Pull the plunger down to the mark on the oral syringe to the dose prescribed by your doctor - this is in milliliters (ml), (figure 5C)

- Turn the bottle the right way up (figure 6A).
- Remove the oral syringe from the adaptor (figure 6B).

- Take the medicine - push the plunger into the oral syringe all the way to the bottom. You can take Briviact directly from the oral syringe. If you take the medicine diluted, empty the contents of the oral syringe into a glass containing water or juice and drink all of the liquid (figure 7).

- Close the bottle with the plastic screw cap.
- Wash the oral syringe with water only (figure 8)

How long to take Briviact for
Briviact is a long term treatment – keep taking Briviact until your doctor tells you to stop.

If you take more Briviact than you should
If you have taken more Briviact than you should, talk to your doctor. You may feel dizzy and sleepy.

If you forget to take Briviact
- If you miss a dose take it as soon as you remember.
- Then take your next dose at the time you would normally take it.
- Do not take a double dose to make up for a forgotten dose.
- If you are not sure what to do, ask your doctor or pharmacist

If you stop taking Briviact
- Do not stop taking this medicine unless your doctor tells you to. This is because stopping treatment could increase the number of fits you have.
- If your doctor asks you to stop taking this medicine they will lower your dose gradually. This helps to stop your fits coming back or getting worse.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.

**Very common:** may affect more than 1 in 10 people
- feeling sleepy or dizzy.

**Common:** may affect up to 1 in 10 people
- flu
- feeling very tired (fatigue)
- convulsion, a feeling of ‘spinning’ (vertigo)
- feeling and being sick, constipation
- depression, anxiety, unable to sleep (insomnia), irritability
- infections of the nose and throat (such as the ‘common cold’), cough
- decreased appetite

**Uncommon:** may affect up to 1 in 100 people
- allergic reactions
- psychotic disorder, being aggressive, thoughts or attempts of harming or killing yourself, nervous excitement (agitation)
- a decrease in white blood cells (called ‘neutropenia’) - shown in blood tests
**Reporting of side effects**
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in **Appendix V**. By reporting side effects you can help provide more information on the safety of this medicine.

5. **How to store Briviact**
- Keep this medicine out of the sight and reach of children.
- Do not use this medicine after the expiry date which is stated on the cardboard box and bottle after EXP. The expiry date refers to the last day of that month.
- After first opening of the bottle, use within 5 months.
- Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. **Contents of the pack and other information**

**What Briviact contains**
The active substance is brivaracetam.
Each millilitre (ml) contains 10 milligrams (mg) brivaracetam.

The other ingredients are: sodium citrate, citric acid anhydrous, methyl parahydroxybenzoate (E218), carmellose sodium, sucralose, sorbitol liquid, glycerol (E422), raspberry flavour, water, purified.

**What Briviact looks like and contents of the pack**
Briviact 10 mg/ml oral solution is slightly viscous, clear, colourless to yellowish liquid.

The 300 ml glass bottle of Briviact is packed in a cardboard box containing a 10 ml oral syringe and an adaptor for the syringe.

**Marketing Authorisation Holder**
UCB Pharma S.A, Allée de la Recherche 60, B-1070 Bruxelles, Belgium.

**Manufacturer**
UCB Pharma S.A., Chemin du Foriest, B-1420 Braine-l’Alleud, Belgium

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

**België/Belgique/Belgien**
UCB Pharma SA/NV
Tél/Tel: + 32 / (0)2 559 92 00

**Литва**
UCB Pharma Oy Finland
Tel: + 358 9 2514 4221 (Suomija)

**България**
Ю СИ БИ България ЕООД
Тел.: + 359 (0) 2 962 30 49

**Чешка republika**
UCB s.r.o.
Tel: + 420 221 773 411

**Магарорша**
UCB Magyarország Kft.
Tel.: + 36-(1) 391 0060
This leaflet was last revised in {month YYYY}.

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu.
This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet
1. What Briviact is and what it is used for
2. What you need to know before you use Briviact
3. How to use Briviact
4. Possible side effects
5. How to store Briviact
6. Contents of the pack and other information

1. What Briviact is and what it is used for

What Briviact is
Briviact contains the active substance brivaracetam. It belongs to a group of medicines called ‘anti-epileptics’. These medicines are used to treat epilepsy.

What Briviact is used for
Briviact is used in adults and adolescents from 16 years of age to treat a type of epilepsy characterized by the occurrence of partial seizures with or without secondary generalization’. Partial seizures are fits that start by only affecting one side of the brain. These partial seizures can spread and extend to larger areas on both sides of the brain – this is called a ‘secondary generalisation’. You have been given this medicine to lower the number of fits (seizures) you have. Briviact is used together with other medicines for epilepsy.

2. What you need to know before you use Briviact

Do not use Briviact if:
- you are allergic to brivaracetam, other pyrrolidone derivatives or any of the other ingredients of this medicine (listed in section 6). If you are not sure, talk to your doctor or pharmacist before taking Briviact.

Warnings and precautions
Talk to your doctor or pharmacist before using Briviact if:
- You have thoughts of harming or killing yourself. A small number of people being treated with anti-epileptic medicines such as Briviact have had thoughts of harming or killing themselves. If you have any of these thoughts at any time, contact your doctor immediately.
- You have liver problems your doctor may need to adjust your dose.

Children and young people
Briviact is not recommended for use in children and young people under 16 years of age.

**Other medicines and Briviact**
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
In particular, your doctor may need to adjust your Briviact dose if you take the following medicines:
- Rifampicin, a medicine used to treat bacterial infections.
- St John’s wort—(also known as Hypericum perforatum) a herbal medicine used to treat depression and anxiety and other conditions.

**Briviact with alcohol**
- Combining this medicine with alcohol is not recommended.
- If you drink alcohol while taking Briviact the negative effects of alcohol may be increased.

**Pregnancy and breast-feeding**
It is not recommended to take Briviact if you are pregnant or breast-feeding, as the effects of Briviact on pregnancy and the unborn baby or the new-born child are not known. Seek advice immediately from your doctor if you are pregnant or are planning to become pregnant.

Do not stop treatment without talking to your doctor first as this could increase your seizures and a worsening of your disease can harm your baby.

**Driving and using machines**
- You may feel sleepy, dizzy or tired while using Briviact.
- These effects are more likely at the start of the treatment or after a dose increase.
- Do not drive, cycle or use any tools or machines until you know how the medicine affects you.

**Briviact contains sodium**
Briviact solution for injection/infusion contains 0.83 mmol (or 19.14 mg) sodium per vial. To be taken into consideration for patients on a controlled sodium diet.

### 3. How to use Briviact

Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

You will use Briviact together with other medicines for epilepsy.
- When you start taking this medicine you will take Briviact orally (as tablets or an oral solution) or be given it as an injection or infusion.
- Briviact solution for injection/infusion is used for a short amount of time when you cannot take Briviact orally.
- You can switch between taking Briviact orally to the solution for injection/infusion, and the other way around.

**How much you will be given**
- The recommended dose is between 50 mg and 200 smg each day, your doctor may decide to adjust your optimal dose within the dose range.
- The medicine is given in two equally divided doses - once in the morning and once in the evening at about the same time each day.

**People with liver problems**
If you have problem with your liver, the maximum dose you will be given is 150 mg each day.

**How Briviact is given**
Briviact is administered as an injection or infusion into a vein by a doctor or a nurse. The medicine is injected slowly into your vein or given as an infusion (drip) over 15 minutes.

**How long to use Briviact for.**
- Your doctor will decide for how many days you will be given the injections or infusion.
- For the long term treatment with Briviact, your doctor will ask you to take Briviact tablets or oral solution.

**If you have more Briviact than you should**
If you think you have been given too much Briviact, tell your doctor straight away.

**If you stop using Briviact**
- Do not stop taking this medicine unless your doctor tells you to. This is because stopping treatment could increase the number of fits you have.
- If your doctor asks you to stop taking this medicine they will lower your dose gradually. This helps to stop your fits coming back or getting worse.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

### 4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

**Very common:** may affect more than 1 in 10 people
- feeling sleepy or dizzy.

**Common:** may affect up to 1 in 10 people
- flu
- feeling very tired (fatigue)
- convulsion, a feeling of ‘spinning’ (vertigo)
- feeling and being sick, constipation
- pain or discomfort at the injection or infusion site
- depression, anxiety, unable to sleep (insomnia), irritability
- infections of the nose and throat (such as the ‘common cold’), cough
- decrease appetite

**Uncommon:** may affect up to 1 in 100 people
- allergic reactions
- psychotic disorder, being aggressive, thoughts or attempts of harming or killing yourself, nervous excitement (agitation)
- a decrease in white blood cells (called ‘neutropenia’) - shown in blood tests

**Reporting of side effects**
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the [national reporting system](#) listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

### 5. How to store Briviact

- Keep this medicine out of the sight and reach of children.
- Do not use this medicine after the expiry date which is stated on the carton and vial after EXP. The expiry date refers to the last day of that month.
- Briviact may be diluted before it is injected by your doctor or nurse. In such cases, it should be used straight after dilution.
- This medicinal product does not require any special storage conditions.
- Each vial of Briviact solution for injection/infusion must be used only once (single use). Any unused solution should be discarded.
- Only clear solution free from particles and discoloration should be used.
- Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Briviact contains
The active substance is brivaracetam.
- Each ml contains 10mg brivaracetam
- Each 5 ml vial contains 50 mg brivaracetam

The other ingredients are: sodium acetate (trihydrate), acetic acid, glacial, sodium chloride, water for injection.

What Briviact looks like and contents of the pack
Briviact 10 mg/ml solution for injection/infusion is a clear, colourless, sterile solution.
Briviact 10 mg/ml solution for injection/infusion 5 ml vial is packed in a carton box of 10 vials.

Marketing Authorisation Holder
UCB Pharma S.A., Allée de la Recherche 60, B-1070 Bruxelles, Belgium.

Manufacturer
UCB Pharma S.A., Chemin du Foriest, B-1420 Braine-l’Alleud, Belgium

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

België/Belgique/Belgien
UCB Pharma SA/NV
Tél/Tel: + 32 / (0)2 559 92 00

България
Ю СИ БИ България ЕООД
Тел.: + 359 (0) 2 962 30 49

Česká republika
UCB s.r.o.
Tel: + 420 221 773 411

Danmark
UCB Nordic A/S
Tlf: + 45 / 32 46 24 00

Deutschland
UCB Pharma GmbH
Tel: + 49 /(0) 2173 48 4848

Ελλάδα
UCB A.E.

Εστονίա
UCB Pharma Oy Finland
Tel: + 358 9 2514 4221 (Soome)

Österreich
UCB Pharma GmbH
Briviact solution for injection/infusion can be administered as a bolus injection or as an infusion:

- Intravenous bolus: may be administered directly without dilution
- Intravenous infusion: may be administered over 15 minutes in a compatible diluent

Briviact may be diluted with the following solutions: sodium chloride 9 mg/ml (0.9 %), glucose 50 mg/ml (5 %) solution for injection or lactated Ringer’s solution. Each vial of Briviact solution for injection/infusion must be used only once (single use). Any unused solution should be discarded (see section 3).
ANNEX IV

SCIENTIFIC CONCLUSIONS AND GROUNDS FOR THE VARIATION TO THE TERMS OF THE MARKETING AUTHORISATION(S)
Scientific conclusions

Taking into account the PRAC Assessment Report on the PSUR(s) for brivaracetam, the scientific conclusions of CHMP are as follows:

Signal: type I hypersensitivity was identified and confirmed for Briviact during the reporting period.

On medical review, 9 cases were suggestive for Type I hypersensitivity. Six out of the 9 cases related to skin manifestations (pruritus [3], erythema [1], rash [1], and urticaria [1]). The remaining cases reported chest discomfort, dyspnea, and flushing, respectively. Four out of the 9 cases were more suggestive that the cause was a Type I hypersensitivity reaction (dyspnea, pruritus [2], urticaria). The events are uncommon and have generally been of mild intensity.

In the view of the data presented in this PSUR, the PRAC Rapporteur considered that changes to the product information of Briviact were warranted. Based on the safety review the PRAC Rapporteur considers that product information update is necessary in order to add safety information regarding the risks of type I hypersensitivity.

In the context of the variation to the terms of the marketing authorization, additional details have added to the text about third BRV metabolite (hydroxy acid) presented in section 5.2 of SmPC.

The CHMP agrees with the scientific conclusions made by the PRAC.

Grounds for the variation to the terms of the marketing authorisation(s)

On the basis of the scientific conclusions for brivaracetam the CHMP is of the opinion that the benefit-risk balance of the medicinal product(s) containing brivaracetam is unchanged subject to the proposed changes to the product information.

The CHMP recommends that the terms of the marketing authorisation(s) should be varied.